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MECHANISMS OF ENHANCED PULMONARY
VASOCONSTRICTION AND CALCIUM SENSITIZATION
FOLLOWING CHRONIC HYPOXIA

by

CHARLES ELBERT NORTON III
B.S. BIOLOGY, B.A. CHEMISTRY, UNIVERSITY OF NEW MEXICO,
2010

ABSTRACT

CH results in pressure dependent basal tone and enhanced
depolarization- and endothelin-1 (ET-1)-induced vasoconstriction in the
pulmonary circulation through Rho kinase (ROK)-dependent Ca2+ sensitization,
responses that may contribute to the development of pulmonary hypertension
(PH) in this setting. The free radical superoxide (O2-) has been implicated in
these responses. Because NADPH oxidases (NOX) play a role in the
development of PH, we hypothesized that membrane depolarization, increases in
iv

intraluminal pressure, and ET-1 signaling lead to pulmonary vascular smooth
muscle (VSM) myofilament Ca2+ sensitization and augmented vasoconstrictor
reactivity following CH through NOX-derived O2- production. As epidermal
growth factor receptor (EGFR) and Src kinases can mediate NOX activation, we
further hypothesized that Src-induced EGFR activation mediates this response.
Vasoconstrictor responses to ET-1 and KCl were greater in Ca2+
permeabilized, endothelium-disrupted, pressurized, pulmonary arteries from CH
(4 wk at 0.5 atm) rats compared to controls, and this effect of CH was abolished
by NOX inhibition. NOX inhibition additionally prevented KCl-dependent O2production in CH arteries. Furthermore, inhibition of EGFR and Src kinases also
prevented augmented ET-1- and KCl-induced vasoconstriction and the
development of basal tone. Rats treated chronically with an EGFR inhibitor
(gefitinib) displayed reduced right ventricular pressure and diminished arterial
remodeling associated with CH-dependent PH. We additionally determined that
vascular smooth muscle membrane depolarization contributes to basal tone but
not vasoconstriction to ET-1 in CH arteries by clamping membrane potential with
valinomycin. Our studies support a novel role for a Src kinase/EGFR/NOX 2
signaling axis in the enhanced pulmonary vascular smooth muscle VSM Ca2+
sensitization, vasoconstriction and PH following CH.
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Chapter 1 – Introduction
PULMONARY HYPERTENSION
Hypoxemia, a reduction in arterial oxygen levels, can be caused by
diminished inspired O2 or by impaired gas transport within the lung. Chronic
hypoxia (CH; Appendix A: Abbreviations and Acronyms, page 148) results from
prolonged exposure to high altitude or as a consequence of conditions that
impede oxygenation of the blood resulting from chronic obstructive pulmonary
diseases (COPD) which has recently risen to the third leading cause of death in
the United States (92) and can result in right heart failure and death. CH causes
pulmonary hypertension (PH), defined clinically as pulmonary arterial pressure
exceeding 25 mmHg at rest (269). Thus, understanding the mechanisms of CHinduced PH is important for the treatment of the disease.
Mechanisms of Chronic Hypoxia-Induced Pulmonary Hypertension
Normally, the pulmonary circulation is a low pressure, low resistance
network of blood vessels. However, under pathological conditions such as CH or
COPD, there are structural and functional changes within the pulmonary
vasculature including vasoconstriction (discussed in next section), vascular
remodeling, and polycythemia (Fig. 1). These changes lead to increases in
pulmonary vascular resistance in accordance with Poiseuille's law:
Resistance= 8ηL/ πr4
where, η is viscosity, L is length, and r is vessel radius. While this equation
relates to resistances in straight, rigid tubes containing a Newtownian fluid, it
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Figure 1: Schematic illustrating contributing factors to chronic hypoxia
(CH)-induced pulmonary hypertension. CH causes vasoconstriction,
vascular remodeling, and polycythemia. These result in elevated vascular
resistance, the development of pulmonary hypertension, and right
ventricular (RV) hypertrophy.
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serves as an approximation for the hemodynamic components that determine
resistance to flow within the pulmonary vasculature.
Polycythemia, an increase in the percent volume of circulating red bloods
cells, results in an increase in blood viscosity, and therefore according to
Poiseuille's law would lead to an increase in pulmonary vascular resistance.
Hypoxia activates hypoxia inducible factor (HIF)-1α which induces the
erythropoiesis that drives the polycythemic response (85; 102).
Erythropoiesis normally occurs at a low basal rate to replace old red blood
cells and can be stimulated when blood loss results in a decrease in the number
of red blood cells and resultant tissue hypoxia. Erythropoietin, the glycoprotein
hormone mediator of this response, is synthesized in the kidney and acts on
erythropoietin receptors on erythroid progenitor cells in the bone marrow to
induce erythropoiesis (54). Other factors that contribute to this response include
testosterone, somatotropin, and insulin-like growth factor 1, although
erythropoietin is necessary for the response (102). This response functions to
maintain red blood cell mass constant day to day and to hasten red blood cell
recovery after hemorrhage.
In response to hypoxia, the transcription factors HIF-1 and HIF-2 result in
an increase in erythropoietin production by fibroblasts in the renal cortex of the
kidney (245; 291). The C-terminus of the HIF-α subunits contains O2-dependent
degradation domains that are prolylhydroxylated in the presence of O2 (28; 99;
100; 308), which leads to ubiquitination and proteasomal degradation (95; 209).
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Therefore, under hypoxic conditionsHIF-1α and HIF-2α levels increase,
facilitating cooperation with the constitutively present HIF-β subunits and the
transcriptional coactivators p300 and cAMP response element-binding protein
(29). These complexes will then bind to the DNA and result in enhanced
transcription of erythropoietin. Hypoxia also decreases GATA-2-dependent
inhibition of erythropoietin synthesis (279). Combined, these actions result in
polycythemia which facilitates greater oxygen carrying capacity in the blood
which serves a beneficial role during hypoxemia. However, polycythemia also
increases blood viscosity and could contribute to elevated pulmonary vascular
resistance during prolonged hypoxia or chronic lung disease.
It has long been understood that structural changes occur within the
pulmonary circulation in response to hypoxia. Studies in CH animals
demonstrated that remodeling of small pulmonary arteries begins within 2 days of
hypoxia exposure (163). This response involves proliferation and hypertrophy of
the smooth muscle and an increase in the muscularization of previously nonmuscularized vessels. Numerous signaling molecules contribute to the vascular
remodeling response including endothelin-1 (ET-1) (4; 49), serotonin (5-HT) (63),
and thromboxanes (123). ET-1, produced by the endothelium, stimulates both
ETA and ETB receptors on pulmonary artery vascular smooth muscle cells,
promoting cell proliferation (43), which contributes to the proliferative response
following hypoxia as ET-1 levels are increased during CH. 5-HT production is
also increased by hypoxia (61) which leads to mitogenesis of smooth muscle and
fibroblasts (299). It is likely that increases in intracellular Ca2+ associated with
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these stimuli plays a key role in the remodeling as increased vascular smooth
muscle (VSM) [Ca2+]i has been linked to remodeling in both human patients
suffering idiopathic PH (73; 309) and animal models of PH (268).
Remodeling also occurs within the adventitial and intimal layer of the
vessel (260). Increased fibroblast and myofibroblast numbers in the vessel wall
substantially contribute to thickening of the vessel wall (230; 249). Endothelial
proliferation and intimal thickening occur in some forms of PH and may contribute
to morphological changes as well (164). Additionally, the recruitment of immune
cells such as macrophages, monocytes, mast cells, dendritic cells, and T-cells
(cytotoxic and T-helper) has been demonstrated in vessels from lungs with
idiopathic PH (238), while decreases in natural killer cells have been observed
(197). Furthermore, these cell types contribute to pulmonary vascular
remodeling in monocrotaline-treated rats (197), and likely contribute to the
inflammatory response associated with PH. These immune cells have been
observed both in the adventitial and intimal layers of the vessel (9; 203; 204; 238;
256; 280). However, the mechanisms by which immune cells contribute to PH
remain to be fully elucidated.
CHRONIC HYPOXIA AND VASOCONSTRICTION
Changes in vessel diameter that occur with vasoconstriction can
additionally be integral in determining pulmonary vascular resistance (Fig. 1).
There are several factors that contribute to elevated vasoconstriction in the
pulmonary circulation including hypoxic pulmonary vasoconstriction, enhanced
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agonist-induced vasoconstriction, and the development of basal arterial tone
(Fig. 2).
The contractile state of VSM is regulated by the level of phosphorylation of
the myosin light chain. The myosin regulatory light chain is phosphorylated by
myosin light chain kinase (MLCK) which facilitates actin myosin interaction and
shortening of the contractile apparatus (272). MLCK is activated by calmodulin.
Calmodulin signaling is set in motion when four Ca2+ ions are bound to it, making
phosphorylation of the myosin light chain dependent upon changes in VSM
[Ca2+]i.
Ca2+-Dependent Vasoconstriction
Pulmonary VSM cells contain L-type voltage gated Ca2+ channels (VGCC)
that couple membrane depolarization to Ca2+ entry. Given that VSM cells
(VSMC) from CH animals are more depolarized than those of control animals
(179), it is likely L-type VGCCs contribute to the elevations inbasalCa2+in the
setting of PH, as rats treated chronically verapamil, an L-type VGCC blocker,
developed reduced hypoxic PH (257). Consistent with this finding are reports
that basal Ca2+ is elevated in the setting of PH (76; 310).
The sarcoplasmic reticulum acts as a Ca2+ sink within the cytoplasm. The
sarcoplasmic endoplasmic reticulum Ca2+ ATPase (SERCA) uptakes Ca2+ from
the cytoplasm. Store operated Ca2+ entry (SOCE) occurs following depletion
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Figure 2. Schematic illistrating mechanisms of vasoconstriction following
CH.
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of the sarcoplasmic reticulum stores leading to further increases in cytosolic Ca2+
(110; 200). Stromal interaction molecule (STIM1) appears to be the Ca2+ sensor
within the sarcoplasmic reticulum that couples store depletion to Ca2+entry (53;
144). While the cellular players mediating this response are still being identified,
roles for canonical transient receptor potential (TRPC) channels, Orai1, and acid
sensing ion channels (ASIC) have been identified (104; 149; 268). SOCE
contributes to enhanced vasoconstriction in CH rats with recognized functions for
STIM1 (144) and ASIC (105; 183; 206) in this response.
Receptor-operated Ca2+ entry (ROCE) contributes to agonist-induced
increases in [Ca2+]i. Diacylglycerol (DAG), produced by phospholipase C
following Gq-coupled receptor stimulation, activates receptor-operated nonselective cation channels to mediate Ca2+ influx. While previous reports from our
laboratory in Sprague Dawley rats demonstrate decreased SOCE and ROCE
following CH (103), SOCE and ROCE are elevated in pulmonary hypertensive
Wistar rats, mice and humans (76; 251; 285; 310).
Ca2+ Sensitization
In addition to increasing VSM [Ca2+]i, many stimuli can also increase the
sensitivity of the contractile apparatus to Ca2+. This is achieved by inhibition of
myosin light chain phosphatase (MLCP). Active MLCP dephosphorylates the
myosin light chain resulting in decreased myosin actin interaction. Agonists that
are coupled to Gq receptors can lead to Ca2+ sensitization through PKC signaling
8

via increases in VSM [Ca2+]i and DAG. PKC is a serine/threonine kinase that
regulates both VSM proliferation and contractility (10; 19). PKC elicits Ca2+
sensitization through phosphorylation of CPI-17 (Thr 38) which subsequently
inhibits the catalytic subunit of MLCP, PP1 (115; 118).
Rho kinase (ROK), another serine/threonine kinase, serves as an
additional mechanism by which Ca2+ sensitization occurs. Binding of the small
GTPase RhoA to the Rho binding domain of ROK causes a conformational
change and activation of the kinase(255). ROK phosphorylates MLCP at two
sites (Thr 696 and Thr 853) (114). Phosphorylation at Thr 697 inhibits MLCP
activity, while phosphorylation at Thr 853 interferes with binding of myosin by the
MYPT1 subunit (65).
CH increases both RhoA activity and ROK expression in pulmonary
arteries (96; 108). This corroborates findings that chronic ROK inhibition
prevents CH-induced PH (96). Studies by Nagaoka and colleagues showed that
ROK is a significant contributor to enhanced pulmonary vascular resistance
following CH (177). These studies demonstrated that acute administration of the
ROK inhibitor drastically decreased pulmonary vascular resistance in CH rats
and nearly normalized pressure to the level of the normotensive control animals
(177). This group also demonstrated that acute inhalation of a ROK inhibitor
decreases pulmonary arterial pressures in fawn-hooded rats which
spontaneously develop PH and in rats with monocrotaline-induced PH (176).
These studies, among others (96; 160), suggest that ROK contributes to the
development of PH via enhanced vasoconstriction.
9

Hypoxic Pulmonary Vasoconstriction
Under normal physiological conditions hypoxic pulmonary vasoconstriction
(HPV) occurs in response to alveolar hypoxia to direct blood flow away from
poorly ventilated (as a result of airway constriction or obstruction) regions of the
lungs. The vasoconstriction then diverts blood to the better ventilated areas of
the lung matching perfusion to the level of alveolar ventilation. In the situation of
chronic hypoxia or COPD, however, where all or most of the lung is hypoxic, this
will lead to elevated pulmonary vascular resistance.
The HPV response has been divided into two phases, phase I and II.
Phase I HPV appears to be intrinsic to the VSM as the response persists
following endothelial disruption (130), and that isolated pulmonary arterial smooth
muscle cells (PASMC) contract in response to acute exposure to hypoxia (152).
Phase I HPV requires Ca2+, and is comparatively short in duration.
There is currently some controversy as to how hypoxia is sensed. Both
theories suggest that mitochondrial reactive oxygen species (ROS) are involved;
however, while one theory suggests there is an increase in ROS, the other
suggests that they are decreased. Archer and colleagues have proposed that
pulmonary arteries have a tonic level of ROS production that is inhibited by
decreased O2 tension (165). This decrease in ROS is proposed to reduce the
cytosol, inhibit K+ channels, depolarize the VSM cell, activate L-type Ca2+
channels, ultimately resulting in contraction (296). Alternatively, an increase in
PASMC mitochondrial ROS in response to hypoxia (215) is proposed to cause
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Ca2+ release from the sarcoplasmic reticulum that activates store operated Ca 2+
entry channels (228; 293) to mediate vasoconstriction. The second phase of
HPV requires the endothelium and is mediated through Ca 2+sensitization (130;
227). Several laboratories have identified a role for endothelin-1 (ET-1) derived
from the endothelium in this response (140; 235). Alternatively, a role for gap
junctions has been proposed in phase II of HPV (119), supporting a role for
coupling of the smooth muscle and endothelium. Additional findings support a
role for conducted depolarization in the endothelium to elicit epoxyeicosatrienoic
acid (EET) release and subsequent vasoconstriction to hypoxia (286).
Interestingly, prolonged exposure to hypoxia blunts the HPV response
(159; 216). This attenuated response appears to be mediated by decreased K +
channel expression and activity (216). While there is still some residual
constriction to acute hypoxia following CH, these findings suggest that other
mechanisms play a larger role in the elevated arterial tone observed following
CH.
Enhanced Vasoconstrictor Sensitivity
The contractile state of the VSM can be influenced by hormones,
neurotransmitters, and other paracrine agents. Many of these factors such as
ET-1, uridine trisphosphate (UTP), and serotonin (5-HT) bind to Gq-coupled
receptors. Gq-coupled signaling results in activation of phospholipase C (PLC)
which cleaves phophatidylinositol 4,5-bisphosphate (PIP2) into inositol
trisphosphate (IP3) and DAG. IP3 binds to and activates IP3 receptors on the
11

sarcoplasmic reticulum, resulting in increases in intracellular [Ca2+]i. The
associated decrease in sarcoplasmic Ca2+ is further capable of mediating SOCE.
DAG is capable of both activation of receptor-operated channels and increasing
PKC activity both of which further lead to vasoconstriction. A role for ROKinduced Ca2+ sensitization has also been identified in pulmonary vasoconstriction
to ET-1 (109).
Active vasoconstriction contributes to PH in humans (151; 170) and rats
(192), as revealed by findings in both species that pulmonary arterial pressure
decreases in response to acute vasodilator inhalation. It has been known for
some time that agonist-induced pulmonary vasoconstriction is augmented in
rodent models of PH, as it was demonstrated that isolated lungs from CH rats
were hyper-responsive to agonists such as angiotensin and prostaglandin F2α
(PGF2α) (159). Later studies have demonstrated enhanced reactivity to U-46619,
ET-1, 5-HT, and norepinepherine in pulmonary hypertensive animals (109; 207;
212; 290). ETA and ETB receptor expression is increased by hypoxia (132). CH
also increases prepro ET-1 mRNA, as well as circulating levels of ET-1 (49),
likely through regulation by HIF-1 (93). In addition to vasoconstriction, ET-1
signaling has also been shown to stimulate the growth of VSM cells (244; 303).
Furthermore, ET-1 receptor inhibition has been shown to prevent hypoxic PH
(196) and reverse established PH (49), suggesting that ET-1-induced
vasoconstriction and vascular remodeling may contribute to CH-induced PH.
Membrane depolarization serves as a vasoconstrictor stimulus in arteries,
including those in the pulmonary circulation. KCl-dependent pulmonary
12

vasoconstriction is augmented in isolated lungs from CH rats (26; 184).
Interestingly, studies in isolated arteries suggest that this mechanism is
dependent on Ca2+ sensitization as pulmonary arteries from CH rats demonstrate
increased vasoconstriction to KCl despite a blunted Ca2+ response compared to
arteries from control animals (26).
Development of Basal Tone
Pressure-dependent VSM tone was first characterized in the systemic
circulation (14). The maintained arterial constriction in response to distending
force exerted by increased intraluminal pressure serves as an autoregulatory
mechanism allowing blood flow to remain relatively constant within small arteries
across various intraluminal pressures (44). Within the pulmonary circulation, little
evidence exists for pressure-dependent tone in the healthy normoxic circulation
(262). However, following CH, pulmonary arteries develop basal tone (27; 177;
304). Our laboratory has found that ROK mediates pressure dependent tone in
arteries from rats with CH-induced pulmonary hypertension (27).
REACTIVE OXYGENSPECIES
Endogenous reactive oxygen species (ROS) are important physiological
second messenger molecules that regulate VSM phenotype (17; 261) and
contractility (17) in the normal pulmonary circulation. ROS are produced in the
endothelial, VSM, and adventitial cells of the blood vessel. Virtually all cell types
within the vasculature are capable of producing both superoxide (O2-) and
hydrogen peroxide (H2O2) (50; 155; 267). O2- is produced when an electron is
13

donated to molecular oxygen (O2). Dismutation of O2- by superoxide dismutase
(SOD) produces H2O2, a more stable ROS. While there is basal O2- production,
constitutive activity of SOD keeps these levels low in the normotensive
pulmonary circulation (302). The resultant H2O2 is eliminated by catalase,
glutathione peroxidase, and peroxiredoxins, which convert H2O2 into H2O and
other metabolites (224).
ROS contribute to the development of PH (46; 60). Excessive ROS
production has been implicated in both the vascular remodeling (98; 138) and
vasoconstrictor responses (69; 109; 138) associated with CH-induced PH. ROS
cause endothelial dysfunction (70; 313). One well known effect of O2- on
vascular contractility arises from its affinity for nitric oxide (NO), which it rapidly
scavenges to form the reactive nitrogen species peroxynitrite (ONOO-) (233).
Oxidative stress within the endothelium is also capable of oxidation of BH4, an
essential cofactor for endothelial nitric oxide synthase (eNOS), leading to eNOS
uncoupling that diminishes NO production and increases O2- production (133).
This diminished NO bioavailability impairs endothelium-dependent dilation that
can be restored by treatment with antioxidants (55; 289). The free radical O2hasalsobeen linked to Ca2+ sensitization and vasoconstriction in VSM of
pulmonary arteries (122). H2O2, conversely, has been shown to have both
vasodilator and vasoconstrictor properties in the pulmonary circulation (30; 136).
Alterations in superoxide dismutase (SOD) levels may also contribute to
the elevated ROS observed following CH. SOD is an enzyme that catalyzes the
conversion of O2- to H2O2. There are three isoforms of SOD, with SOD1 located
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in the cytoplasm, SOD2 in the mitochondria, and SOD3 in the extracellular
space.SOD1 and 3 utilize copper and zinc as cofactors, whereas SOD2, the
mitochondrial enzyme, has manganese in its reactive center. Many forms of
pulmonary hypertension are associated with dysfunction of SOD (6; 48; 68; 112;
188; 206; 214). Indeed levels of SOD1 and SOD3 are reduced in both rodent
and piglet models of pulmonary hypertension (48; 68; 206), while reduced SOD2
expression has been observed in fawn hooded rats and humans with idiopathic
pulmonary hypertension (Group I) (6; 237). Reductions in SOD activity
exacerbate increases in ROS production from enzymatic sources and may
facilitate basal tone and enhanced vasoconstriction following CH. Changes in
the regulation of H2O2 degradation in animal models of PH also has the potential
to regulate pulmonary arterial ROS levels (206).
Hypoxia has been demonstrated to increase pulmonary arterial ROS
levels (116; 287). An increase in vasoconstrictor reactivity is associated with this
increase in ROS in pulmonary hypertensive piglets, and the source of ROS in
this setting appears to be NADPH oxidase (NOX) (69). O2--dependent RhoA
activation also contributes to enhanced pulmonary vasoconstrictor reactivity
following CH though Ca2+ sensitization mechanisms (26; 109). While the ROS
species contributing to this response appears to be O2-, the vascular source of
this factor has not yet been identified (Fig. 3). However, experiments
demonstrating increased vasoreactivity to KCl and ET-1 in endothelium-disrupted
pulmonary arteries suggest that endothelial sources of ROS, such as uncoupled
eNOS, do not directly contribute to this response (26; 109; 184).

15

Figure 3. Increases in intraluminal pressure, membrane depolarization, and
ETR signaling lead to ROK-dependent Ca2+ sensitization in pulmonary
VSM.
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Enzymatic Sources of ROS
One source of ROS within the vasculature is NOX. NOX isoforms are the
only enzymes whose primary function is the production of ROS. NOX subtypes
1, 2, and 4 are the most abundant forms in VSM (153), and they are a major
source of O2- in the smooth muscle and endothelium (169). The catalytic
subunits of NOX 1 and 2 are activated by phosphorylation of the cytosolic
subunits NOXO1 and NOXA1 in the case of NOX 1, and p47phox and p67phox in
the case of NOX 2 ( Fig. 4) (21; 38; 153). A small GTP-binding protein, Rac1, is
also a critical signaling mediator of both NOX 1 and 2 signaling (21; 38). NOX 4
does not contain the cytosolic regulatory subunits of NOX 1 and 2 (21; 38).
Alterations in NOX expression and function have been identified in
multiple forms of PH. CH increases expression of NOX 4 in pulmonary arteries
(168), whereas NOX 2 has been shown to contribute to the development of CHinduced PH in mice (138). Furthermore, Rac1 and p47phox expression are
elevated in lungs from pulmonary hypertensive lambs (81).
Another source of vascular ROS is the mitochondria. Under normal
physiological conditions, the mitochondria convert up to 5% of molecular oxygen
to O2- (199). Generally mitochondrial ROS are buffered by antioxidants such as
SOD2 (64). However, pulmonary hypertensive chickens have increased ROS
production mediated by dysfunction of mitochondrial complexes I and III (97).
Preliminary findings from our laboratory support a role for mitochondrial ROS in
the development of intermittent hypoxia-induced PH (253).
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Figure 4. Schematic of NADPH oxidase 2 components including
membrane components Rap1, p21phox, and gp91phox, cytosolic subunits
p47phox, p67phox, and p40phox, and Rac1 in inactive (A) and active (B) states.
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Xanthine oxidase (XO) is an additional source of ROS within the
vasculature. It is an enzyme that catalyzes oxidative hydroxylation of purine
substrates and generates O2-. XO can be activated by hypoxia in cultured
PASMCs (88).

Additional studies found that hypoxia increases lung XO activity

and that treatment of rats with allopurinol, a XO inhibitor, blunts CH-induced PH
and associated pulmonary vascular remodeling (91).
Interestingly, membrane depolarization and membrane stretch may
activate NOX in macula densa (142) and endothelial cells (32; 158; 254),
whereas G-protein-coupled receptor (GPCR) stimulation in the systemic
circulation can result in vasoconstriction via NOX (180). Therefore, NOX
enzymes serve as likely candidates for ROS production following depolarization,
membrane stretch, and ET-1 receptor (ETR) signaling in the hypertensive
pulmonary circulation.
EPIDERMAL GROWTH FACTOR RECEPTOR
The epidermal growth factor receptor (EGFR) plays a role in the
development of monocrotaline-induced PH in rats (42; 162) and mediates PH in
mice that overexpress transforming growth factor (TGF)-α (129). EGFR is a
1186-amino acid growth factor receptor that is primarily stimulated by the ligands
EGF and TGF-α and is involved in growth and proliferation (297; 319). It is well
established that upon ligand binding to EGFR there is an increase in receptor
dimerization and autophosphorylation of the tyrosine 845 residues followed by
enzyme activation (306; 307). This is associated with migration of EGFR from
lipid domains in the plasma membrane to the general membrane component
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(166). EGFR activation is also characterized by phosphorylation on the
tyrosine1068 residue (13; 74).
EGFR is an upstream activator of NOX and Rac 1 in glomerular mesangial
cells (314) and of RhoA in renal tubule epithelial cells (111). Interestingly,
depolarization can activate EGFR in both PC12 cell and cardiomyocytes (56;
270; 318). EGFR also contributes to the development of myogenic tone in the
systemic circulation (5), suggesting that it could play a role in the mediation of
pressure-dependent basal tone following CH. Additionally, EGFR signaling has
been implicated in systemic vasoconstriction to agonists such as angiotensin II
(15), phenylepherine (87; 281), and enhanced pulmonary vasoconstriction to KCl
(184).
SRC FAMILY KINASES
Src family kinases are potential candidates for mediating EGFR activation
following CH. They are a group of 9 kinases characterized by its prototypical
member c-Src. As intracellular proteins with no known ability to detect changes
in the extracellular milieu, activation of Src family kinases is regulated by other
cell surface receptors (23; 35; 148; 205; 223; 250). Many cellular processes are
regulated by Src family kinases, including focal adhesion formation, migration,
cell cycle progression, apoptosis, differentiation, and gene transcription (3; 25;
275). Growth factor receptors are key initiators of Src kinase signaling (23; 25).
Additionally, focal adhesion kinases can interact with Src family kinases where
they play an essential role in events resulting from activation of integrins (205;
223). Activation of Src kinases is achieved through protein-protein interactions
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involving the phosphotyrosine binding Src homology domain 2 (SH2) and SH3
regions (20; 39; 175). Phosphorylation of the tyrosine 416 residue also
contributes to kinase activation (232).
Src family kinases can be activated by an array of GPCRs (35; 125; 148;
250). Some data point to a direct interaction between Src and Gα subunits
(150). Many GPCRs contain SH3 binding motifs (137), and other data indicate a
role for GPCR phosphorylation in this response (62). Src family kinases couple
membrane stretch to Rac1 and NOX signaling through EGFR-dependent
mechanisms in mesangial cells (314). Additionally, NOX1 is involved in
angiotensin II-mediated hypertension in the systemic circulation (157). These
findings make Src kinases a prime candidate for coupling depolarization,
membrane stretch, and ETR receptor stimulation to EGFR-dependent NOX
activation and ROS production following CH (184).
Src kinases can activate EGFR either directly (18; 236; 263) or through
matrix metalloproteinases (87; 146; 190; 234). Src can directly phosphorylate
EGFR on two residues, Tyr-1101 and Tyr-845 (18). However, Src dependent
ligand cleaving can also result in EGFR activation. The best characterized
mechanism of EGFR activation in through a process known as ectodomain
shedding (208). The principle ligands of EGFR are synthesized as precursor
molecules that can be proteolyzed to produce soluble ligands. The primary
classes of molecules implicated in this response are matrix metalloproteinases
and ADAMs (a disintegrin and a metalloproteinase) (7; 82; 208).
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MATRIX METALLOPROTEINASES
Matrix metalloproteinases (MMPs) are a class of zinc-dependent enzymes
(193). They are involved in the degradation of numerous extracellular proteins,
but can additionally produce bioactive ligands (229; 259). MMPs can be
regulated by tissue inhibitors of metalloproteinases (TIMPs). TIMPs 1-4 have
been identified mammals (22). TIMPs are capable of inhibiting all MMPs except
for MMP14 (300).
Alterations in MMP expression have been detected in numerous forms of
PH (72; 89; 156; 241; 242), although the general trend is for increased
expression. Findings by Lepetitet. al. show increased MMP2 activity and
decreased MMP3 expression in arteries from patients with idiopathic PH (131).
Consistent with this result, increased MMP2 and 9 expression and activity were
observed in rats with monocrotaline- and hypoxia-induced PH (72; 124; 240;
284). Endothelial (240), VSM (213; 226), and adventitial fibroblast (167) cells are
all capable of MMP production in a variety of vascular beds. Interestingly, MMP2
production in pulmonary arterial fibroblasts can be increased by hypoxia (167),
and maternal hypoxia increases MMP2 and MMP9 activity in neonatal rat brains
(276). Additional MMPs may be secreted by immune cells within the vasculature
(294).
Some of the best characterized roles for MMPs in the pulmonary
vasculature are growth and angiogenesis (283). Members of the gelatinase
family (due to their ability to degrade gelatin), particularly MMPs 2 and 9, are
critical for sprouting angiogenesis (283). MMPs are capable of regulation of
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proliferation, migration, and apoptosis of endothelial cells and VSMCs (211; 283;
311).
While little is known about the role of MMPs in pulmonary
vasoconstriction, several isoforms have been implicated in systemic
vasoconstriction. Agonist-induced activation of MMP-7 contributes to EGFRdependent vasoconstriction in the mesenteric circulation of Sprague-Dawley rats
(87). MMPs 2 and 9 have been shown to be involved in EGFR transactivation
and myogenic tone in the murine circulation (146), while MMP 2 has been
implicated in the development of angiotensin II-induced hypertension (189).
Interestingly, Src kinases can activate both of these MMPs in T cells (243).
ADAMs area family of metalloproteases that are closely related to MMPs.
EGF cleaved by ADAM-17 contributes to cell proliferation of cancer cells and
angiogenesis (195). Intriguingly, ADAM-17 has also been shown to be critical
mediator of angiotensin II-induced EGFR activation in aortic VSM and hepatic
stem cells (190; 191), and has additionally been linked to ET-1 receptor signaling
(234). Additionally, while regulation of ADAM-17 expression can be regulated by
HIF in synovial cells (31), very little is known about the role of these proteins in
PH.
RATIONALE AND SPECIFIC AIMS
Pulmonary vascular dysfunction resulting from CH leads to increased
pulmonary vascular resistance and PH in patients with COPD and in residents at
high altitude. It is widely considered that pulmonary arterial constriction is central
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to this disease process. Vasoconstrictor responses to CH are multifaceted,
including acute hypoxic pulmonary vasoconstriction, elevated basal tone, and
enhanced vasoconstrictor reactivity to both membrane depolarizing stimuli and
many receptor-mediated agonists. Studies from our laboratory have revealed a
prominent role for RhoA-mediated myofilament Ca2+ sensitization in each of
these vasoconstrictor components (26; 27; 109). However, the mechanisms that
link vascular smooth muscle (VSM) stretch, vasoconstrictor receptors, and
membrane depolarization to RhoA-dependent vasoconstriction in the
hypertensive pulmonary circulation are largely unknown. Our lack of knowledge
regarding mechanisms by which CH mediates pulmonary VSM contraction is an
important problem, because without it, we are unlikely to understand the
significance of the relevant signaling pathways to the etiology of PH or to develop
effective treatments and preventative measures for this condition. Therefore, the
overall objective of this study was to determine mechanisms by which CH
imparts pulmonary basal tone and augmented receptor-mediated
vasoconstriction. We have previously reported that enhanced agonist- and
depolarization-induced VSM Ca2+ sensitization following CH is mediated by ROS
(26; 109). Furthermore, CH leads to greater pressure-dependent depolarization
and vasoconstriction compared to small pulmonary arteries from control rats (26;
184). However, whether membrane depolarization-induced ROS generation
contributes to elevated basal tone and vasoconstriction in hypertensive
pulmonary arteries had not been previously established. Experiments showing
that NOX 2 knockout mice do not develop PH (138) suggest that NOX 2 could be
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the source or ROS mediating the studied responses. Furthermore, EGFR and
Src kinases have been implicated in stretch-dependent NOX activation in
mesangial cells (179; 314) providing the rationale for the investigation of these
two proteins in the studied responses. Therefore, our studies investigated the
central hypothesis that chronic hypoxia confers basal pulmonary arterial
tone and augmented depolarization-induced and receptor-dependent
vasoconstriction through Src/EGFR/NOX 2 signaling and myofilament Ca2+
sensitization. We tested this hypothesis by addressing the following specific
aims:

Specific Aim 1.
Establish the contribution of NOX 2 signaling to enhanced pulmonary
arterial vasoconstrictor reactivity following CH.
Hypothesis and Approach.
We hypothesized that CH imparts basal tone and enhances
depolarization-induced and ET-1-dependent vasoconstriction in small pulmonary
arteries through NOX 2-mediated myofilament Ca2+ sensitization. Protocols for
this study employed isolated, pressurized small pulmonary arteries (100-200 m
ID) from control and CH rats using a preparation that allows simultaneous
measurement of ID and vessel wall [Ca2+]i or ROS production at physiological
intraluminal pressures. To minimize complicating influences of the endothelium,
all experiments were conducted in vessels disrupted of endothelium. These
experiments were performed in the presence and absence of NOX 2 and Rac1
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inhibition. NOX 2 expression and Rac1 activity were also measured in
pulmonary arteries.
Specific Aim 2.
Identify the role of EGFR and Src kinase signaling in augmented
pulmonary vasoconstrictor reactivity following CH
Hypothesis and Approach.
We hypothesized that CH-dependent basal tone and enhanced
depolarization-induced and ET-1-mediated vasoconstriction require Src/EGFR
signaling. Experiments in this aim were designed to address the contribution of
EGFR and Src to enhanced vasoconstrictor reactivity and ROS production in
isolated small pulmonary arteries following CH and determine the effects of Src
and EGFR inhibition on Rac1 activation. We further tested a role for MMPs in
enhanced vasoconstriction to ET-1. Additional experiments examined the
contribution of EGFR to the development of PH by measuring right ventricular
pressure, right ventricular hypertrophy, and vascular remodeling in animals
treated chronically with an EGFR inhibitor or its vehicle.
Specific Aim 3.
Assess the contribution of pressure-dependent and ET-1-induced
membrane depolarization to augmented pulmonary vasoconstrictor reactivity
following CH.
Hypothesis and Approach.
Pulmonary VSM is depolarized in arteries from CH rats compared to
controls. As previously stated, while membrane depolarization can activate L-
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type Ca2+ channels and lead to constriction, we have observed a direct effect of
membrane depolarization to lead to Ca2+ sensitization, independent from L-type
channel activation that occurs in arteries from CH rats (27). Increases in
intraluminal pressure (likely through stretch-activated cation channels in
pulmonary VSM) and ET-1 receptor stimulation can result in pulmonary VSM
membrane depolarization (179; 248). We hypothesized that CH increases
vasoconstrictor responsiveness by coupling stretch and ET-1-mediated VSM
membrane depolarization to myofilament Ca2+ sensitization. Protocols for this
aim assessed arterial diameter, vessel wall [Ca2+]i, and membrane potential in
the presence and absence of the potassium ionophore valinomycin to clamp
membrane potential in order to determine the contribution of depolarization to
enhanced vasoconstrictor reactivity in arteries from CH rats. The ability of
membrane depolarization to mediate vasoconstriction to ET-1 was tested in a
similar manner.
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Chapter 2 – Methods
GENERAL METHODS
Experimental Groups and Chronic Hypoxic Exposure Protocol
Male Sprague Dawley rats (Harlan Industries, ~300-380g) were used for
all studies. CH rats were housed in hypobaric chambers maintained at a
pressure of ∼380 mmHg for four weeks (27; 109; 179; 220). Age matched
control rats were housed in an adjacent room at ambient pressure (∼630 mmHg
in Albuquerque, NM). All animals were maintained on a 12:12-h light-dark cycle.
All protocols employed in this study were reviewed and approved by the
Institutional Animal Care and Use Committee of the University of New Mexico
School of Medicine (Albuquerque, NM).
Indices of Pulmonary Hypertension
Right Ventricular Hypertrophy and Polycythemia
Right ventricular hypertrophy was assessed as an index of PH as
described previously (217; 220). After isolation of the heart, the atria and major
vessels were removed from the ventricles. The right ventricle (RV) was then
separated from the left ventricle and septum (LV + S). The sections of the heart
were then weighed and Fulton's index (RV/LV+S) was used to assess the degree
of right ventricular hypertrophy.

Polycythemia was assessed by measuring

hematocrit (%) from blood collected in microcapillary tubes following direct
cardiac puncture.
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Right Ventricular Pressure
Right ventricular systolic pressure (RVSP) was measured as an index of
pulmonary arterial pressure in anesthetized rats (2% isoflurane and 98% O2 gas
mixture). An upper transverse laparotomy was performed to expose the
diaphragm. A 25-gauge needle, connected to a pressure transducer (model P23
XL, Spectramed), was inserted into the RV via a closed-chest transdiaphragmatic
approach, and the transducer output amplified by a Harvard Instruments
amplifier. All data were recorded, and heart rate was calculated with a computerbased data-acquisition system (AT-CODAS, DATAQ Instruments).
Arterial Wall Thickness
Following assessment of right ventricular pressures, lungs were fixed
similar to experiments our laboratory has performed previously (217; 218). After
a median sternotomy, heparin (100 U in 0.1 ml) was injected directly into the right
ventricle. The pulmonary artery was then cannulated with a 13-gauge needle
stub, and the trachea was cannulated with a 17 gauge needle stub. The
preparation was immediately perfused at 0.8 ml/min by a Masterflex
microprocessor pump drive (model 7524-10) with physiological saline solution
(PSS) containing (in mM) 129.8 NaCl, 5.4 KCl, 0.5 NaH2PO4, 0.83 MgSO4, 19
NaHCO3, 1.8 CaCl2, and 5.5 glucose with 4% bovine serum albumin (wt/vol)
added as a colloid. Papaverine (10−4 M) was also included in the PSS to maintain
the vasculature in a dilated state during subsequent fixation. The left ventricle
was cannulated with a plastic tube (4 mm outer diameter). The perfusion rate
was gradually increased to 60 ml·min−1·kg body wt−1. Perfusate was pumped
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through a water-jacketed bubble trap maintained at 38°C before entering the
pulmonary circulation. Experiments were performed with lungs in zone three
conditions, achieved by elevating the perfusate reservoir until venous pressure
(Pv) was ∼12 mmHg. Previous work from our laboratory suggests that maximal
recruitment and thus maximal vascular surface area is achieved at this flow and
Pv(57). The vasculature was initially washed with 250 ml of PSS, followed by 250
ml of fixative (0.1 M phosphate-buffered saline with 4% paraformaldehyde, 0.1%
gluteraldehyde, and 10−4 M papaverine). Lungs were additionally inflated with
fixative via the trachea to a pressure of 25 cm H2O during perfusion. The trachea
was ligated with 2-0 silk, the arterial and venous lines simultaneously clamped,
and the lungs immersed in fixative. A transverse section (2–3 mm thick) of tissue
from the left lobe was removed and rinsed in phosphate-buffered saline. Sections
were dehydrated in increasing concentrations of ethanol, cleared in xylene, and
mounted in paraffin.
Transverse sections of the left lung were cut (4 μm thick) and mounted
onto Superfrost Plus slides (Fisher Scientific). Sections were stained for elastin
(Sigma Accustain Elastic Stain kit), and arteries were identified by the presence
of an internal elastic lamina(217; 219). Vessels were examined with a ×40
objective on a Nikon Optiphot microscope, and images were generated with a
digital charge-coupled device camera (Photometrics CoolSNAP) and processed
with MetaMorph software (Universal Imaging). Measurements were performed on
16-51 arteries (<50 μm inner diameter) and 4–25 arteries (50–100 μm diameter)
per rat from 5 rats/group. These measurements assessed from the outer margin
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of the external elastic lamina, and luminal (80) diameter and were made using a
blinded analysis. External and internal arterial diameters were calculated from
the medial the medial and luminal circumferences, respectively. Arterial wall
thickness was assessed by subtracting luminal radius from external radius and
expressed as a percentage of external diameter according to the following
formula:

[(2X wall thickness)/external diameter] X 100

Additional lung sections were prepared to examine changes in the number
of fully and partially muscularized arteries (183). Sections were incubated with
rabbit anti-smooth muscle α-actin (1:200, Abcam) overnight at 4°C. Smooth
muscle α-actin was detected by incubating the slides with DyLight 549-donkey
anti-rabbit (1:400, 3.5 h, Jackson ImmunoResearch). Twenty images from the
right and left lobes were randomly collected per animal using a ×20 objective on
a confocal microscope (TCS SP5, Leica). Numbers of fully and partially
muscularized arteries were counted per animal.

Isolation of Small Pulmonary Arteries
Rats were anesthetized with pentobarbital sodium (200 mg/kg ip), and the
heart and lungs were exposed by midline thoracotomy. The heart and left lung
were removed and immediately placed in cold PSS. A 4th or 5th order
intrapulmonary artery [∼150 µm inner diameter (ID)] without side branches,
approximately ∼1mm in length, was dissected free from the lung parenchyma
and transferred to a Living Systems vessel chamber. The proximal end of the
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artery was cannulated with a tapered glass pipette and held in place by a single
strand of silk ligature. The artery was then gently flushed with PSS to remove
blood from the lumen and a strand of moose mane was inserted into the distal
end of the artery to disrupt the endothelium. Endothelial disruption allows for the
focus on VSM function independent of endothelial influences. The distal end of
the artery was then cannulated and pressurized to 12 mmHg with a servocontrolled peristaltic pump (Living Systems). The absence of vessel leakage was
confirmed by turning off the servo-control function and ensuring the vessel
maintained pressure. All vessels with apparent leaks were discarded (26; 27;
109).
Measurement of Vessel Diameter
Isolated, cannulated pressurized vessels were transferred to the stage of
a Nikon Eclipse TS100 microscope for measurement of changes in vessel
diameter (Fig. 5). This setup allows for assessment of VSM function
independent of circulating factors, innervation, or shear stress. The preparation
was superfused with PSS equilibrated with a 10% O2, 6%, CO2, and balance N2
gas mixture and maintained at 37 °C. A vessel chamber cover was position to
allow this same gas mixture to flow over the top of the vessel chamber bath. An
Imaging Source camera was used to obtain bright-field images of the vessels
and dimensional analysis was performed by IonOptix software to measure ID by
edge detection. A viability check was performed to by constriction to 5 µM UTP
as previously reported (27; 109). Endothelial disruption was confirmed by lack of
a vasodilatory response to 1 µM acetylcholine (ACh).
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Figure 5: Representative image of isolated pulmonary artery from a CH rat.
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To directly assess mechanisms of myofilament Ca2+ sensitization
independent of changes in vessel wall [Ca2+]i, we clamped [Ca2+]i in some
arteries by permeabilizing with the Ca2+ ionophore, ionomycin (3 µM, Sigma), as
previously described(109). All Ca2+ permeabilized vessels were equilibrated with
PSS containing a calculated free Ca2+ concentration of 300 nM. This
concentration of Ca2+ was chosen to provide optimal vasoreactivity to KCl while
having minimal effects on resting tone based on preliminary studies.
Measurement of Vessel Wall [Ca2+]i
Pressurized arteries (Fig. 5) were loaded abluminally with the ratiometric,
Ca2+ sensitive, fluorescent indicator fura-2 AM (Molecular Probes) as previously
described (27; 103; 107; 108; 184; 185; 251). Prior to loading, fura-2 AM (1mM
in anhydrous DMSO) was mixed 2:1 with a 20% solution of pluronic acid
(Invitrogen). This mixture was diluted in PSS, resulting in a final concentrationof2
µM fura-2 AM and 0.05% pluronic acid. Arteries were incubated in this solution
for 45 minutes at room temperature while being equilibrated with a 10% O2 gas
mixture. Subsequently, vessels were rinsed for 20 minutes with aerated PSS (37
°C) to wash out excess dye and facilitate hydrolysis of AM groups by intracellular
esterases. Fura-2-loaded vessels excited alternatively at 340 and 380 nm with
an IonOptix Hyperswitch dual excitation light source, and the respective 510 nm
emissions we collected by a photomultiplier tube. Background-subtracted
340/380 emission ratios were calculated with IonOptix Ion Wizard Software and
recorded simultaneously with ID measurements (described above) throughout
the experiment.
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Measurement of DHE Fluorescence in Pulmonary Arteries
Fluorescence detection of dihydroethidium (DHE; Molecular Probes)
oxidation was used as a measure of O2-levels in pressurized, endotheliumdisrupted, Ca2+-permeabilized arteries from control and CH rats, as reported
previously (26; 109; 184; 185). Cells are permeable to DHE, which is converted
to the fluorescent products ethidium and 2-hydroxyethidium in an O2--dependent
manner (315). Arteries were prepared for experimentation as described above
and transferred to the stage of a Nikon Diaphot microscope. After 30 min of
equilibration, arteries were loaded with DHE (10 µM DHE and 0.05% pluronic
acid). Vessels were incubated in this solution for 30 min at room temperature in
the dark and then rinsed for 5 min with PSS (37°C) to wash out excess dye.
Fluorescent images were obtained using a standard tetramethylrhodamineisothiocyanate (TRITC, excitation ~550 nm and emission ~600 nm)
filter before (for background subtraction) and after loading the vessel with DHE.
Images (1 per minute) were generated with a charge-coupled device camera
(PhotometricsSenSys 1400) and processed with MetaFluorsoftware (Molecular
Devices). Normalized fluorescence intensity is defined as average gray-scale
values for all pixels in the field above background.
Membrane Potential Measurement
Small pulmonary arteries prepared as described above were used to
measure VSM membrane potential. Arteries were maintained at 12 mmHg
unless otherwise stated. VSM cells were impaled with microelectrodes (50- to
100-MΩ tip resistance) containing 3 M KCl from the adventitial surface.
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Membrane potential was recorded with a Neuroprobe amplifier (model 1600, A-M
Systems). Analog output from the amplifier was low-pass filtered at 1 kHz and
sent to a Tektronix RM502A oscilloscope and Dataq data acquisition system.
Membrane potential recordings used for analysis contained 1) a sharp negative
deflection in potential and the microelectrode was advanced into the cell, 2) a
stable Em for at least 30 seconds, and 3) an abrupt return to ~0 mV following
retraction of the electrode from the cell. Movement of vessels in response to
changes in pressure and KCl or ET-1 stimulation prevented the acquisition of
continuous recordings from the same cell. Therefore membrane potential was
recorded in several (4-6) cells under both baseline conditions and in response to
stimulation. The mean membrane potential of all VSM cells recorded from a
single artery under each set of conditions were averaged into a single n for
statistical purposes (179; 184).
Measurement of DHE Fluorescence in Isolated PASMCs
Pulmonary arterial smooth muscle cells (PASMC) were isolated from
arteries from CH and control rats treated with papain (9.5 U/mL, Sigma),
collagenase (1750 U/mL, Sigma), and dithiothreitol (1 mM, Sigma) in reduced
Ca2+ HBSS at 37 °C for 30 min. The cell suspension was placed on glass cover
slips and cultured for 3-4 days in Ham's F-12 media with 5% fetal bovine serum
and 1% penicillin streptomycin in a humidified incubator in an atmosphere of 5%
CO2-95% air at 37 °C. PASMC were treated with HEPES PSS containing ET-1
(10-8 M), ET-1+AG1478 (EGFR inhibitor), or vehicle conditions to determine the
role of EGFR in ET-1-stimulated O2- production. Cells were then treated with the
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fluorescent O2- indicator DHE (5 µM in 0.05% pluronic acid, Molecular Probes)
and the nuclear stain TO-PRO®-3 (1:2,000, Molecular Probes) for 15 minutes at
37 °C and subsequently fixed in 2% paraformaldehyde (206).

Fluorescent

images were acquired with a 63X objective on a Leica confocal microscope.
Mean fluorescence intensity was averaged from 5 images/animal. Each image
was thresholded using ImageJ (NIH) to select for positively stained areas above
background (cells not treated with DHE).
Western Blotting
Pulmonary arteries collected from the entire pulmonary arterial tree were
dissected in ice-cold HEPES-PSS and snap frozen in liquid N2. Samples were
homogenized in 10 mM Tris-HCl containing 255 mM sucrose, 2 mM EDTA, 12
μM leupeptin, 4 μM pepstatin A, 1 μM aprotinin (Sigma) and centrifuged at
10,000 g at 4°C to remove insoluble debris, following which the supernatant was
collected. Pulmonary artery lysates were separated by SDS-PAGE (Tris·HCl
gels, Bio-Rad) and transferred to polyvinylidenedifluoride membranes. Blots were
blocked for 1 hr at RT with 5% milk and 0.05% Tween 20 (Bio-Rad) in Trisbuffered saline (TBS) containing 10 mM Tris-HCl and 50 mM NaCl (pH 7.5).
Primary antibodies were incubated overnight. Some blots were labeled by
chemiluminescence (ECL, Pierce Thermo Scientific) and bands were detected by
exposing the blots to chemiluminescence-sensitive film (KODAK). These blots
were normalized to total protein as assessed by Coomassie staining. Other blots
were incubated with a fluorescent secondary antibody and then imaged on an
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Odyssey fluorescent imaging system (LI-COR). Total protein expression was
normalized to the level of β-actin. Bands were quantified using ImageJ.
Calculations and Statistics
All data are expressed as means ± SE. Values of n refer to number of
animals in each group. A t-test, one-way ANOVA, two-way ANOVA, or repeated
measures ANOVA was used to make comparisons when appropriate. If
differences were detected by ANOVA, individual groups were compared with the
Student-Newman-Keuls or Bonferroni test. A probability of P < 0.05 was
considered significant for all comparisons.

PROTOCOLS FOR SPECIFICAIM 1
Establish the contribution of NOX 2 signaling to enhanced pulmonary
arterial vasoconstrictor reactivity following CH.
Protocol Series 1.1: Role of NOX 2 in depolarization-induced
vasoconstriction following CH.
Vessel ID and vessel wall [Ca2+]i were measured in response to increasing
depolarizing concentrations of KCl (30-120 mM KCl) in small, endothelium
disrupted, pulmonary arteries from CH and control rats as described above (26;
184). Some vessels were permeabilized to Ca2+ in order to focus on the Ca2+
sensitization component of the vasoconstriction response. We confirmed that
arteries were Ca2+ permeabilized by loading arteries with fura-2AM and
measuring vessel wall [Ca2+]i. Experiments were performed in the presence of
the NOX inhibitors apocynin (30 µM, Sigma) (261) and DPI (10 µM, Sigma) (301)
in addition to the specific NOX2 inhibitor gp91ds-tat or its scrambled control
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peptide (50 µM, Tufts) (221; 222) (Fig. 6). We confirmed that gp91ds-tat did not
alter membrane potential with sharp electrode measurements. These
experiments were repeated in arteries pretreated with the Rac1 inhibitor
NSC23766 (50 μM, Cayman) (143) or vehicle to identify the contribution of the
NOX2 accessory protein, Rac1, to depolarization-dependent vasoconstriction
and ROS production following CH. NSC23766 was chosen for its selectivity for
Rac1 over other members of the Ras family, particularly RhoA. To further
characterize the ROS species mediating this response, vasoconstrictor
responses to KCl were assessed in arteries from CH and control rats in the
presence of polyethylene glycol (PEG)-SOD (120 U / mL, Sigma) (70), PEGcatalase (250 U / mL, Sigma) (48), or vehicle.
In parallel protocols, we determined effects of NOX inhibition on
depolarization-induced O2- generation in isolated arteries from CH and control
rats using the fluorescent indicator dihydroethidium (DHE) (17). We conducted
these experiments in the presence of apocynin, gp91ds-tat, NSC23766 or their
respective vehicles to determine the contribution of NOX 2 and Rac1 in
mediating increased depolarization-induced ROS production in pulmonary
arteries from CH rats. To determine the effect of depolarization on Rac1 activity
and expression, western blots were performed on homogenatesofCa2+
permeabilized intrapulmonary arteries from CH and control rats stimulated with
60 mM KCl or vehicle. Using a GTP-pulldown assay (Cytoskeleton) (314), GTP
bound Rac1 (indicative of activation) was normalized to total Rac1.
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Figure 6: Diagram of experimental protocols for Specific Aim 1.

40

Protocol Series 1.2: Contribution of NOX 2 to CH-induced basal tone.
Vessel diameter and vessel wall [Ca2+]i were measured in small
pulmonary arteries in response to increasing intraluminal pressure steps (5-45
mmHg). In contrast to Protocol series 1.1, arteries used for basal tone
measurements were not Ca2+ permeabilized as the development of basal tone is
not associated with a significant change in Ca2+ (27). We performed pressure
steps under both Ca2+-containing and Ca2+-free conditions. Basal tone was
calculated as the percent difference in ID between Ca2+ containing and Ca2+ free
conditions at each pressure step (Fig. 7) (27). To evaluate the contribution of
NOX 2 to this response, vasoconstrictor and Ca2+ responses to increasing
intraluminal pressure were measured in arteries from CH and control rats in the
presence of apocynin, gp91ds-tat, or their respective vehicles. These
experiments were repeated in arteries pretreated with the Rac1 inhibitor,
NSC23766, the ROS scavengers PEG-SOD and PEG-catalase, or vehicle.
Protocol Series 1.3: Role of NOX 2 in augmented ET-1-mediated
vasoconstriction following CH.
Similar to Protocol Series 1.1, vessel ID and vessel wall [Ca2+]i were
measured in response to increasing concentrations of ET-1 (10-10-10-7 M, Sigma)
in Ca2+ permeabilized pulmonary arteries from CH and control rats in the
presence of gp91ds-tat, or its scrambled control peptide to determine the
contribution of NOX to enhanced ET-1 constriction following CH.
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Figure 7: Pressure-dependent arterial tone was assessed by increasing
intraluminal pressure in 10 mmHg steps under Ca2+-replete and Ca2+-free
conditions. Arterial tone was calculated as the % difference in vessel ID
between Ca2+-replete and Ca2+-free conditions.
Pressure-dependent arterial tone was assessed by increasing intraluminal
pressure in 10 mmHg steps under Ca2+-replete and Ca2+-free conditions.
Arterial tone was calculated as the % difference in vessel ID between Ca2+replete and Ca2+-free conditions.
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Protocol Series 1.4: Effects of CH on pulmonary arterial NOX expression.
NOX 2 expression was compared between intrapulmonary arteries from
CH and control rats by western blotting (as described in the general protocol
section). Pulmonary arterial NOX 2 catalytic subunit expression was measured
using a mouse monoclonal NOX 2 (gp91phox) antibody (1:2,000, BD Biosciences)
(59). Expression was normalized to β-actin to account for any variance in protein
loading.
PROTOCOLS FOR SPECIFIC AIM 2
Identify the role of EGFR and Src kinase signaling in augmented
pulmonary vasoconstrictor reactivity following CH.
Protocol Series 2.1: Role of EGFR and Src in enhanced depolarizationinduced vasoconstriction following CH.
Depolarization-induced vasoconstriction and ROS production were
assessed in the presence and absence of the EGFR inhibitor AG 1478 (1 μM,
Cayman) in Ca2+ permeabilized pulmonary arteries from CH and control rats
similar to Protocol Series 1.1 (Fig. 8). This concentration of AG1478 prevents
stretch induced EGFR activation in mesangial cells (314). We additionally
examined the role of Src in mediating enhanced depolarization-induced
vasoconstriction using the Src inhibitors SU6656 (10 μM, Cayman) and PP2 (10
μM, Cayman). These Src inhibitors at the stated concentrations have been
shown to prevent Src activation in mesangial cells in work that was corroborated
by siRNA (314).
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Figure 8: Diagram of Specific Aim 2 assessing the role of Src kinases and
EGFR in enhanced vasoconstrictor reactivity following CH.
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Similar to protocols measuring Rac1 activity (Aim 1), we measured EGFR
activation (indicated by phosphorylation of the tyrosine residue 1068 (13; 74) by
western blot with antibodies for both phospho-EGFR (1:500, Cell Signaling) in
pulmonary arteries from CH and control rats (314). These experiments
compared pulmonary arterial homogenates stimulated with 60 mM KCl or
vehicle. Phospho-EGFR was normalized to total EGFR expression (1:500, Cell
Signaling) (314). We assessed the role of EGFR in mediating depolarizationinduced Rac1 activation following CH by measuring Rac1 activity in the same
manner as Protocol Series 1.1, but in the presence and absence of the EGFR
inhibitor AG 1478.
Protocol Series 2.2: Role of EGFR and Src in basal tone following CH.
Pulmonary arterial ID and vessel wall [Ca2+]i were measured in response
to increasing pressure steps as described in Protocol Series 1.2 in the presence
or absence of the EGFR inhibitors AG 1478 and gefitinib (1 μM, Cayman).
These protocols were repeated in the presence of the Src kinase inhibitor
SU6656.
Protocol Series 2.3: Contribution of EGFR and Src to enhanced ET-1mediated vasoconstriction following CH.
We measured vasoconstrictor responses to ET-1 in Ca2+ permeabilized
arteries from control ad CH rats as described in Protocol Series 1.3 in the
presence or absence of AG 1478 and SU6656. Src kinase phosphorylation
(1:1,000, Cell Signaling) (273) on tyrosine 416 (indicative of activation) was
measured by western blot in pulmonary arterial homogenates from CH and
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control rats and normalized to total Src kinase expression (1:1,000, Cell
Signaling) (273). To assess the role of EGFR in ET-1 induced ROS production,
we measured DHE fluorescence in isolated PASMCs from CH and control rats
treated with vehicle, ET-1, or ET-1 and AG-1478.
Protocol Series 2.4: Mechanisms of EGF-induced vasoconstriction.
To determine whether CH induces this pathway at the point of EGFR or
downstream, ID and vessel wall [Ca2+]i were measured in non-Ca2+ permeabilized
arteries from CH and control rats in response to increasing concentrations of
EGF (Sigma). Experiments were performed in the presence of HA1077 (10 μM,
Sigma), gp91ds-tat, AG 1478, and SU 6656 to determine the roles of ROK, NOX,
EGFR, and Src kinases respectively.
Protocol Series 2.5: Role of matrix metalloproteinases in enhanced
pulmonary vasoconstriction following CH.
To determine if EGFR is being activated by Src kinases though MMP
dependent (18; 236; 263) or MMP independent mechanisms (87; 146; 190; 234),
the broad spectrum MMP inhibitor GM6001 (15 μM, Millipore) (37) was used to
examine the role of metalloproteinases in augmented vasoconstriction to ET-1
following CH similar to protocols 1.3 and 2.3 (Fig. 9). Subsequent experiments
examined effects of inhibitors of ADAM 17 (TAPI-1, 10 µM, Santa Cruz) (174),
MMP 2 [MMP 2 inhibitor 3 (also known as ARP 100), 100 nM, Millipore] (189),
and MMP9 (MMP 9 inhibitor 2, 10 µM, Millipore) (52) on this response. MMP 2
inhibitor 3 has a relatively high selectivity at this dose for MMP 2 (IC50 values:
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Figure 9: Diagram of Specific Aim 2.5 examining the role of MMPs in
enhanced vasoconstriction to ET-1 following CH.
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MMP 2, 12 nM; MMP 9, 200 nM; MMP 1, 50µM; MMP 3, 3 µM; MMP 7, 50 µM)
(178; 231), while MMP 9 inhibitor 2 is targeted to the hemopexin domain that
exists on MMP 9, but not other MMPs (52).
Western blots were performed to determine potential changes in MMP
expression following CH. Primary antibodies to ADAM 17 (1:1,000, Abcam) (24),
MMP2 (1:500, Abcam) (240) and MMP 9 (1:2,500, Abcam) (240) were used to
determine if CH alters expression of these proteins.
Protocol Series 2.6: Role of ETR in metabotropic transduction of
membrane depolarization and increased intraluminal pressure to enhanced
vasoreactivity following CH.
As some GPCRs have been implicated in transducing both
mechanical(113; 161) and depolarizing stimuli (141; 154) to VSM contraction, we
hypothesized that ETR function as a proximal signaling mediator coupling
membrane depolarization and vessel wall stretch to myofilament Ca2+
sensitization and vasoconstriction following CH. To test this hypothesis, we
assessed pressure-dependent basal tone and vasoconstrictor responses to KCl
in pulmonary arteries similar to previous protocols. Experiments were performed
in the presence of both the selective ETA receptor agonist BQ-123 (10 μM,
Sigma) and the ETB antagonist BQ-788 (10 μM, Sigma) (109) to determine if
membrane depolarization or membrane stretch transduce their signal through
ETRs. These ETR antagonists, at the used concentrations, have been shown to
nearly abolish ET-1 mediated vasoconstriction in pulmonary arteries (109).
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Protocol Series 2.7: Contribution of EGFR to CH-induced PH.
To determine if EGFR is critical in the development of CH-induced PH, we
treated CH and control animals daily with pills containing the EGFR inhibitor
gefitinib (30 mg/kg/day, Cayman), or vehicle pills (Bioserv dough with 10%
peanut butter). This concentration of drug administered orally for 14 days was
able to attenuate monocrotaline-induced PH in Sprague-Dawley rats (42). We
then measured right ventricular pressure (RVP), right ventricular hypertrophy,
vascular remodeling, and hematocrit in these animals as we have done
previously in our laboratory (general methods) (217; 219).

PROTOCOLS FOR SPECIFIC AIM 3
Assess the contribution of pressure-dependent and ET-1-induced
membrane depolarization to augmented pulmonary vasoconstrictor reactivity
following CH.
Protocol Series 3.1: Contribution of membrane depolarization in CHdependent basal tone.
Pressure-response curves were conducted in the presence of the K+
ionophore valinomycin (5 μM, Sigma) (288) and 16 mM KCl to normalize VSM
membrane potential in CH arteries to that of control arteries and to prevent
stretch-induced depolarization (Fig. 10). Using the Nernst equation to predict
membrane potential, and assuming K+ is the only membrane permeant ion, 16
mM extracellular K+ in combination with valinomycin should set membrane
potential to ~-60 mV (membrane potential of a control artery under
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Figure 10: Diagram of experimental protocols for Specific Aim 3.
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baseline conditions). The ability of valinomycin to prevent depolarization was
validated using sharp electrode measurement of membrane potential.
Assessment of pressure-dependent basal tone was further evaluated in separate
sets of arteries from each group treated with pinacidil (100 μM, Sigma) (106;
128), an ATP-sensitive potassium channel (KATP) agonist, to hyperpolarize VSM
membrane potential.

This concentration of pinacidil is able to nearly maximally

dilate the pulmonary circulation in isolated saline perfused lungs (106). These
experiments with pinacidil were performed in the presence of the L-type Ca2+
inhibitor diltiazem (50 μM, Sigma) (26) to prevent changes in VSM [Ca2+]i
resulting from alterations in membrane potential.
Protocol Series 3.2: Role of membrane depolarization in receptor-mediated
vasoconstriction following CH.
Vasoconstrictor responses to ET-1 were measured in Ca2+ permeabilized
arteries treated with valinomycin and 16 mM KCl as in Protocol Series 3.1 in
order to examine the potential contribution of membrane depolarization to
enhanced vasoconstriction to ET-1 in CH arteries. The ability of valinomycin to
prevent depolarization to ET-1 was validated using sharp electrode measurement
of membrane potential.
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Chapter 3 – Results
General
CH resulted in polycythemia (hematocrit of62.0 ± 3.4% in CH rats and
46.7 ± 2.7% in controls, n=89-92/group) and right ventricular hypertrophy
(RV/LV+S of 0.55 ± 0.01 in CH rats and 0.28 ± 0.01 in controls, n=28/group)
indicative of the development of PH consistent with previous observations in our
laboratory (16; 217; 219; 252). CH also elevated RVSP (Fig. 11A) and resulted
in increased arterial wall thickness in small pulmonary arteries (<50 μm diameter,
Fig. 11B).
SPECIFIC AIM 1
Establish the contribution of NOX 2 signaling to enhanced pulmonary
arterial vasoconstrictor reactivity following CH.
Hypothesis:
We hypothesize that CH imparts basal tone and enhances depolarizationinduced and ET-1-dependent vasoconstriction in small pulmonary arteries
through NOX 2-mediated myofilament Ca2+ sensitization.
Role of NOX 2 in depolarization-induced vasoconstriction following CH
The role of NOX, as a source of O2-, in mediating enhanced membrane
depolarization-dependent vasoconstriction following CH was initially tested in
nonpermeabilized pulmonary arteries using the general NOX inhibitor apocynin.
Apocynin decreased reactivity to KCl in CH arteries, while having no effect in
control arteries (Fig. 12 A) supporting a role for NOX in this response.
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Figure 11. CH leads to increased RVSP and arterial remodeling. Peak
right ventricular pressures (A) and arterial wall thickness (B) following CH
or control exposure. Values are means ± SE n=5/group; *p<0.05 vs.
control.
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Figure 12. Augmented KCl-induced vasoconstriction following CH is
NOX-dependent
in
nonpermeabilized
pulmonary
arteries.
2+
Vasoconstrictor responses (A) and vessel wall Ca
(B) to KCl in
pressurized, endothelium-disrupted pulmonary arteries from CH and
control rats in the presence of the NOX inhibitor apocynin (30 µM) or
vehicle. Values are means ± SE n=5-7/group; *p<0.05 vs. respective
control. #p<0.05 CH apocynin vs. CH vehicle.
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Interestingly, KCl caused an increase in vessel wall Ca2+ in control arteries, but
not CH arteries (Fig. 12B).
To more directly address the role of NOX in enhanced depolarizationdependent VSM Ca2+ sensitization following CH, we further examined effects of
NOX inhibitors on KCl-dependent vasoconstriction in Ca2+-permeabilized
arteries. The nonselective NOX inhibitors apocynin (Fig. 13A) and DPI (Fig. 13B)
attenuated KCl-dependent vasoconstriction in arteries from CH, but not control
rats, and normalized responses between groups. Similar inhibitory effects were
observed using the specificNOX2 inhibitory peptide, gp91ds-tat (also known as
Nox2ds-tat) (41), compared to the scrambled peptide (Fig. 14A). We detected no
differences in basal Ca2+ and observed no Ca2+ responses to KCl in arteries
treated with apocynin, DPI, or gp91ds-tat (Fig. 14B).
O2- production was measured by fluorescence detection of
dihydroethidium (DHE) oxidation in endothelium-disrupted, Ca2+-permeabilized
arteries from control and CH rats pressurized to 12 mmHg. CH exposure
resulted in elevated basal and KCl-induced O2-levels in pressurized pulmonary
arteries (Fig.15). In contrast, KCl did not alter O2- production in control arteries. In
arteries from CH animals, apocynin lowered basal DHE fluorescence to the level
of controls, while both apocynin and DPI prevented KCl-dependent increases in
O2- production (Fig. 15A and 15B, respectively). gp91ds-tat also decreased
basal DHE fluorescence compared to the scrambled peptide in arteries from CH
rats, and prevented the effect of KCl to elevate DHE fluorescence in these
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Figure 13. NOX is required for greater KCl-mediated Ca2+ sensitization
and constriction in Ca2+ permeabilized arteries from CH rats.
Vasoconstrictor responses to KCl in pressurized, Ca2+ permeabilized,
endothelial disrupted pulmonary arteries from CH and control rats in the
presence of the NOX inhibitors (A) apocynin (30 µM), DPI (50 µM), or
vehicle. Values are means ± SE n=4-5/group; *p<0.05 vs. control. #p<0.05
vs. CH vehicle.
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Figure 14 Enhanced KCl-mediated vasoconstriction and Ca2+
sensitization in arteries from CH rats requires NOX 2. Vasoconstrictor
(A) and Ca2+ (B) responses to KCl in pressurized, Ca2+ permeabilized,
endothelium disrupted pulmonary arteries from CH and control rats in the
presence of the specific NOX 2 inhibitor, gp91ds-tat (50 µM), or its
scrambled control peptide. Values are means ± SE n=4-5/group; *p<0.05
vs. control. #p<0.05 vs. CH vehicle.
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Figure 15. CH-induced increases in basal and depolarizationstimulated O2- levels in pressurized arteries are NOX-dependent. DHE
fluorescence under basal conditions and following administration of KCl (60
mM) in pressurized, endothelium-disrupted, Ca2+ permeabilized pulmonary
arteries from CH and control rats in the presence of (A) apocynin, (B) DPI,
or their respective vehicles. KCl was administered 1 min into recording.
Values are means ± SE n=4-5/group; *p<0.05 vs. control at each time
point. #p<0.05 vs. CH vehicle. τp<0.05 vs. CH vehicle.
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vessels (Fig. 16), suggesting that NOX 2 plays a primary role in depolarization
induced O2- generation and pulmonary vasoconstriction.
To confirm that inhibitory influences of gp91ds-tat on KCl-induced
vasoconstriction and production in CH arteries were not due to the peptide
causing VSM membrane hyperpolarization, we measured membrane potential
with sharp electrodes in pressurized arteries from each group. In accordance
with previous findings (26), VSM membrane potential was depolarized in arteries
from CH rats under both basal and KCl-stimulated conditions (Fig. 17). Inhibition
of NOX 2 was without effect on membrane potential in arteries from either group.
Previous work from our laboratory has demonstrated that the O2- spin trap
agent, tiron, prevents enhanced vasoconstriction to KCl following CH exposure
(26). To further characterize the ROS involved in this response, we assessed
the relative contributions O2- and H2O2 to enhanced KCl-induced vasoconstriction
following CH. Experiments were conducted in the presence of the O 2scavenger, PEG-SOD, or the H2O2 scavenger, PEG catalase. Similar to tiron
(26), PEG-SOD attenuated reactivity to KCl in pulmonary arteries from rats
exposed to CH, while having no effect in control vessels (Fig. 18A). In contrast,
PEG-catalase did not alter vasoconstriction to KCl in either group (Fig. 18B).
We next wanted to determine if the NOX component Rac1 plays an
important role to mediate this response. To test this possibility, we measured
depolarization-induced vasoconstriction and DHE fluorescence in the presence
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Figure 16. NOX 2 is necessary for CH-induced increases in basal and
depolarization-stimulated O2- levels in pressurized arteries. DHE
fluorescence under basal conditions and following administration of KCl (60
mM) in pressurized, endothelium-disrupted, Ca2+ permeabilized pulmonary
arteries from CH and control rats in the presence of the specific NOX 2
inhibitor, gp91ds-tat (50 µM), or its scrambled control peptide. KCl was
administered 1 min into recording. Values are means ± SE n=4-5/group;
*p<0.05 vs. control at each time point. #p<0.05 vs. CH vehicle. τp<0.05 vs.
CH vehicle.
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Figure 17. NOX 2 inhibition does not alter pulmonary VSM membrane
potential. Sharp electrode measurements (raw trace and mean data) of
membrane potential in response to KCl in pressurized, Ca 2+ permeabilized,
endothelial disrupted pulmonary arteries from CH and control rats in the
presence of the specific NOX 2 inhibitor, gp91ds-tat (50 µM), or its
scrambled control peptide. Values are means ± SE n=4-5/group; *p<0.05
vs. control. #p<0.05 vs. CH vehicle.
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Figure 18. O2-, but not H2O2, mediates depolarization-induced
myofilament Ca2+ sensitization and constriction in Ca2+ permeabilized
arteries from CH rats. Vasoconstrictor responses to KCl in pressurized,
endothelium-disrupted, Ca2+ permeabilized pulmonary arteries from CH
and control rats in the presence of (A) PEG-SOD (120 U/mL) or (B) PEGcatalase (250 U/mL). Values are means ± SE n=4-5/group; *p<0.05 vs.
control. #p<0.05 vs. CH vehicle. τp<0.05 vs. CH catalase vs. CH SOD.
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or absence of the Rac1 inhibitor NSC 23766. Similar to our findings with NOX
inhibition, Rac1 inhibition prevented KCl-mediated increases in vasoreactivity
(Fig. 19) and DHE fluorescence (Fig. 20) in CH arteries, while having no effect in
control arteries. Similar to effects of O2- scavenging (109; 184) or NOX inhibition
(Figs. 15 and 16), Rac1 inhibition prevented elevated basal O2- levels in arteries
from CH rats.
KCl-dependent Rac1 activation was assessed by performing a Rac1-GTP
pulldown assay in ionomycin-treated (300nM Ca2+) pulmonary arteries from
control and CH rats. While not significant, Rac1-GTP tended to be increased in
arteries from CH rats under basal conditions (Fig. 21). KCl stimulation caused a
robust increase in Rac1 activation in arteries from rats exposed to CH, while
having no significant effect in control arteries. No differences were detected in
total Rac1 expression (normalized to β actin, Fig. 22).
Contribution of NOX 2 to CH-induced basal tone
The role of NOX as a source of O2- mediating basal arterial tone
development following CH was tested in nonpermeabilized pulmonary arteries
using the NOX inhibitors apocynin and gp91ds-tat. Both general NOX (Fig. 23)
and specific NOX 2 (Fig. 24A) inhibition attenuated the development of pressuredependent basal tone in CH arteries while having no effect in control arteries.
Vessel wall Ca2+ was not different between CH and control arteries at any
pressure step (Fig. 24B).
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Figure 19. Enhanced depolarization-dependent vasoconstriction
following CH requires Rac1. Vasoconstrictor responses to KCl in
pressurized, Ca2+ permeabilized, endothelial disrupted pulmonary arteries
from CH and control rats in the presence of the Rac1 inhibitor, NSC 23766
(50 µM), or its vehicle. Values are means ± SE n=4/group; *p<0.05 vs.
control. #p<0.05 vs. CH vehicle.
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Figure 20. Rac1 is necessary for CH-induced increases in basal and
depolarization-stimulated O2- levels in pressurized arteries. DHE
fluorescence under basal conditions and following administration of KCl (60
mM) in pressurized, endothelium-disrupted, Ca2+ permeabilized pulmonary
arteries from CH and control rats in the presence and absence of the NSC
23766 (50 µM). KCl was administered 1 min into recording. Values are
means ± SE n=4/group; *p<0.05 vs. control at each time point. #p<0.05 vs.
CH vehicle.
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Figure 21. Depolarization mediates Rac1 activation in arteries from
CH rats.
Mean densitometric data for GTP bound (active) Rac1
normalized to total Rac1 in homogenates from control and CH
intrapulmonary arteries. Active Rac1 was measured under baseline
conditions, and following 10 min stimulation with KCl (60 mM). Values are
means ± SE n=4/group; *p<0.05 vs. control KCl. #p<0.05 vs. CH vehicle.
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Figure 22. Rac 1 expression is not altered by CH. Mean densitometric
data for total Rac1 normalized to β-actin in arterial homogenates from
control and CH intrapulmonary arteries.
Values are means ± SE
n=8/group; no significant differences were detected.
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Figure 23. Pressure-dependent basal tone in arteries from CH rats
requires NOX. Basal arterial tone (% of passive ID) as a function of
increasing intraluminal pressure in arteries from CH and control rats in the
presence of the NOX inhibitor apocynin (30 μM) or its vehicle. All arteries
were endothelium-disrupted. Values are means ± SE n=4-5/group;
*p<0.05 vs. control. #p<0.05 vs. CH vehicle.
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Figure 24. Pressure-dependent basal tone in arteries from CH rats
requires NOX 2. Basal arterial tone (% of passive ID, A) and vessel wall
Ca2+ (B) as a function of increasing intraluminal pressure in arteries from
CH and control rats in the presence of the NOX 2 inhibitor gp91ds-tat (50
μM), or its scrambled control peptide. All arteries were endotheliumdisrupted.
Values are means ± SE n=4-5/group; *p<0.05 vs. control.
#p<0.05 vs. CH vehicle.
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To address the role of Rac1 in this response, experiments were repeated in the
presence of the Rac1 inhibitor NSC 23766. Similar to NOX inhibition, blocking
Rac1 activation prevented the development of basal arterial tone (Fig. 25).
Previous reports suggest that O2- is the ROS responsible for basal tone
development following CH (27). To further characterize the ROS species
involved in this response, pressure step protocols were conducted in the
presence of the O2- scavenger, PEG-SOD, or the H2O2 scavenger, PEG
catalase. PEG-SOD attenuated pressure-dependent basal tone in pulmonary
arteries from rats exposed to CH, while having no effect in control vessels (Fig.
26A). In contrast, PEG-catalase did not alter responses in either group (Fig.
26B).
Role of NOX 2 in augmented ET-1-mediated vasoconstriction following CH
We examined the effect of gp91ds-tat on ET-1-dependent vasoconstriction
in Ca2+ permeabilized arteries to determine if NOX 2 is important in mediating
agonist-induced Ca2+ sensitization. Similar to KCl-induced vasoconstriction (Fig.
12), NOX 2 inhibition attenuated vasoconstriction to ET-1 in arteries from CH, but
not control rats (sample trace Fig. 27, mean data Fig. 28). Responses between
CH and control groups treated with the NOX 2 inhibitor were not different from
each other. Inhibition of the NOX component, Rac1, additionally prevented
enhanced vasoconstrictor sensitivity to ET-1 in arteries from CH rats (Fig. 29).
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Figure 25. Pulmonary basal tone requires Rac1. Basal arterial tone in
the presence or absence of the Rac1 inhibitor NSC 23766 (50 μM). All
arteries were endothelium-disrupted. Values are means ± SE n=4-5/group;
*p<0.05 vs. control. #p<0.05 vs. CH vehicle.
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Figure 26. O2-mediates pressure-dependent pulmonary basal tone
following CH. Basal arterial tone in pressurized, endothelium-disrupted,
pulmonary arteries from CH and control rats in the presence of (A) PEGSOD or (B) PEG-catalase. Values are means ± SE n=4-5/group; *p<0.05
vs. control. #p<0.05 vs. CH vehicle.
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Figure 27. Sample trace of ET-1 constriction in a Ca2+ permeabilized
artery. Raw traces of vasoconstrictor responses to ET-1 and vessel wall
Ca2+ in a pressurized, endothelium-disrupted Ca2+ permeabilized
pulmonary artery from a CH rat.
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Figure 28. Augmented ET-1-induced vasoconstriction following CH is
NOX 2-dependent.
Vasoconstrictor (A) and vessel wall Ca2+ (B)
responses to ET-1 in pressurized, endothelium-disrupted Ca2+
permeabilized pulmonary arteries from CH and control rats in the presence
of the NOX 2 inhibitory peptide gp91ds-tat (50 µM) or its scrambled control
peptide. Values are means ± SE n=5-7/group; *p<0.05 vs. respective
control. #p<0.05 CH gp91ds-tat vs. CH scrambled.

74

Figure 29. Augmented ET-1-induced vasoconstriction following CH is
Rac1-dependent. Vasoconstrictor responses to ET-1 in pressurized,
endothelium-disrupted pulmonary arteries from CH and control rats in the
presence of the Rac1 inhibitor NSC23776 (50 µM) or vehicle. Values are
means ± SE n=4-5/group; *p<0.05 vs. respective control. #p<0.05 CH
NSC23776 vs. CH vehicle.
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Effects of CH on pulmonary arterial NOX expression
To address whether enhanced pulmonary vasoreactivity and O 2production following CH are associated with an increase in NOX 2 expression,
we measured levels of the catalytic subunit of NOX 2 (gp91phox) in intrapulmonary
arteries from CH and control rats. However, we observed no difference in NOX 2
levels between control and CH arterial homogenates when normalized to β actin
expression (Fig. 30).
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Figure 30. Pulmonary arterial NOX 2 expression is not altered by CH
exposure. Representative Western blots and mean densitometric data for
NOX 2 and β actin in intrapulmonary arteries from CH and control rats.
Values are means ± SE n=4/group. There were no significant differences.
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Aim 1 Major Findings



NOX 2 mediates augmented KCl-dependent pulmonary arterial
vasoconstriction, Ca2+ sensitization, and O2- production following CH (Figs. 14
and 16).



Basal tone in arteries from pulmonary hypertensive animals requires NOX 2
(Fig. 24).



The enhanced pulmonary arterial constriction to ET-1 following CH requires
NOX 2 (Fig. 28).



Rac1 is required for both basal tone and enhanced vasoconstrictor sensitivity
to KCl and ET-1 in pulmonary arteries from animals exposed to CH (Figs. 19,
25, and 29).



Pulmonary arterial NOX 2 catalytic subunit expression (gp91phox) is
unaltered by CH exposure (Fig. 30).
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SPECIFIC AIM 2
Identify the role of EGFR and Src kinase signaling in augmented
pulmonary vasoconstrictor reactivity following CH.
Hypothesis:
We hypothesize that CH-dependent basal tone and enhanced
depolarization-induced andET-1-mediated vasoconstriction require Src/EGFR
signaling.
Role of EGFR and Src in enhanced depolarization-induced
vasoconstriction following CH
To address the contribution of EGFR to enhanced depolarizationdependent VSM Ca2+ sensitization following CH, we further examined effects of
the EGFR inhibitor AG 1478 on KCl-dependent vasoconstriction in Ca2+permeabilized arteries. AG 1478 attenuated KCl-dependent vasoconstriction in
arteries from CH rats, while having no effect on arteries from control animals
(Fig. 31). Inhibition of EGFR also normalized responses between groups.
Additionally, to determine the effects of EGFR inhibition on ROS production, we
measured DHE fluorescence over time following administration of KCl in
pulmonary arteries in the presence and absence of the EGFR inhibitor. In
contrast to NOX or Rac1 inhibition (Figs. 15,16, and 20), inhibition of EGFR did
not prevent the effect of CH to increase basal O2- generation (Fig. 32). However,
AG 1478 prevented KCl-dependent increases in DHE fluorescence in the arteries
from rats exposed to CH.
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Figure 31.
EGFR is necessary for enhanced KCl-mediated
vasoconstriction and Ca2+ sensitization in arteries from CH rats.
Vasoconstrictor responses to KCl in pressurized, Ca2+ permeabilized,
endothelial disrupted pulmonary arteries from CH and control rats in the
presence of the EGFR inhibitor, AG 1478 (1 µM), or its scrambled control
peptide. Values are means ± SE n=4-5/group; *p<0.05 vs. control.
#p<0.05 vs. CH vehicle.
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Figure 32. EGFR contributes to CH-dependent increases in
depolarization-stimulated O2- levels in pulmonary arteries. DHE
fluorescence under basal conditions and following administration of KCl (60
mM) in pressurized, endothelium-disrupted, Ca2+ permeabilized pulmonary
arteries from CH and control rats in the presence or absence of AG 1478
(1 µM). KCl was administered 1 min into recording. Values are means ±
SE n=4-5/group; *p<0.05 vs. control at each time point. #p<0.05 vs. CH
vehicle. τp<0.05 vs. CH vehicle.
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Next, we sought to define the signaling relationship between EGFR and
KCl-dependent Rac1 activation in Ca2+-permeabilized pulmonary arteries from
control and CH rats with a Rac1-GTP pull-down assay. EGFR inhibition
abolished KCl-induced increases in Rac1 activity observed in CH arteries (Fig.
33).
EGFR activity was assessed as the ratio of phosphorylated (Tyr 1068) to
total EGFR levels. Basal levels of phosphorylated EGFR were not different
between control and CH arteries (Fig. 34). KCl led to an increase in active
(phosphorylated) EGFR in CH arteries while having no effect in control arteries.
No differences were detected in total EGFR expression (normalized to β actin,
Fig. 35).
We next tested the role of Src kinases in this response with the inhibitors
PP2 and SU6656. Similar to EGFR and NOX inhibition, blockade of Src kinases
attenuated KCl-induced vasoconstriction in pulmonary arteries from CH rats (Fig.
36). Interestingly, at the highest concentration of KCl (120 mM) Src kinase
inhibition did not fully normalize reactivity to the level of controls.
Contribution of EGFR and Src to basal tone following CH
We hypothesized that similar to depolarization-dependent
vasoconstriction, EGFR and Src kinases are important mediators of pressuredependent basal arterial tone in arteries from pulmonary hypertensive rats.
Consistent with this hypothesis, we observed that the EGFR inhibitors AG 1478
and gefitinib prevented pressure-dependent tone in pulmonary arteries from CH
rats (Fig. 37 A and B). We additionally sought to examine the role of Src kinase
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Figure 33. Depolarization mediates EGFR-dependent Rac1 activation
in arteries from CH but not control rats. Representative Western blots
and mean densitometric data for GTP bound (active) Rac1 normalized to
total Rac1 in homogenates from control and CH intrapulmonary arteries.
Active Rac1 was measured under baseline conditions, and following 10
min stimulation with KCl (60 mM) or KCl plus the EGFR inhibitor AG1478
(1 µM). Values are means ± SE n=4/group; *p<0.05 vs. control KCl.
#p<0.05 vs. CH vehicle. τp<0.05 vs. CH KCl.
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Figure 34. EGFR phosphorylation is induced by KCl in arteries from
CH but not control rats. Representative Western blots and mean
densitometric data for phosphorylated (active) EGFR normalized to total
EGFR in pulmonary arterial homogenates from control and CH
intrapulmonary arteries. Phosphorylated and total EGFR were measured
under baseline and KCl-stimulated (60 mM) conditions. Values are means
± SE n=7/group. *p<0.05 vs. control KCl. #p<0.05 vs. CH vehicle.
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Figure 35. EGFR expression is not altered by CH. Mean densitometric
data for EGFR in intrapulmonary arteries from normoxic and CH rats
normalized to β-actin expression. Values are means ± SE n=14/group; no
significant differences were detected.
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Figure 36. Enhanced KCl-dependent vasoconstriction and Ca2+
sensitization in arteries from CH rats requires Src. Vasoconstrictor
responses to KCl in pressurized, Ca2+ permeabilized, endothelial disrupted
pulmonary arteries from CH and control rats in the presence of the Src
inhibitors SU6656 (10 µM) and PP2 (10 µM). Values are means ± SE n=45/group; *p<0.05 vs. control. #p<0.05 vs. CH vehicle.
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Figure 37. Enhanced pressure-dependent arterial tone in arteries from
CH rats requires EGFR. Pressure-dependent tone in pressurized,
endothelial disrupted pulmonary arteries from CH and control rats in the
presence of the EGFR inhibitors AG 1478 (1 µM, A) and gefitinib (50 µM),
or their respective vehicles. Values are means ± SE n=4-5/group; *p<0.05
vs. control. #p<0.05 vs. CH vehicle.
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in this response by repeating the basal tone protocol in the presence and
absence of Src kinase inhibition. We found that inhibition of Src kinases with SU
6656 similarly prevented the development of basal tone (Fig. 38).
Role of EGFR and Src in enhanced ET-1-mediated vasoconstriction
following CH
We assessed the contribution of EGFR to enhanced agonist-dependent
VSM Ca2+ sensitization following CH by examining effects of AG 1478 on ET-1dependentvasoconstriction in Ca2+-permeabilized arteries. EGFR inhibition
attenuated ET-1-dependent vasoconstriction in arteries from CH rats, while
having no effect on the arteries from control animals (Fig. 39). Similar to effects
of Src kinase inhibition to attenuate CH-induced basal tone and enhanced KCldependent vasoconstriction (Figs. 38 and 36 respectively), SU 6656 inhibition
also prevented enhanced vasoreactivity to ET-1 resulting in similar responses
between groups (Fig. 40).
Basal and ET-1 stimulated ROS production was measured by DHE
fluorescence in isolatedCa2+-permeabilized PASMCs from CH and control rats.
DHE fluorescence was not different between control and CH cells (Fig 41). ET-1
selectively increased DHE fluorescence in PASMCs from rats exposed to CH,
while having no effect in control PASMCs. The EGFR inhibitor, AG 1478,
prevented ET-1 induced increases in DHE fluorescence in cells from CH rats
resulting in similar fluorescence between groups.
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Figure 38. Src kinases are necessary for CH-dependent basal tone.
Pressure-dependent basal tone in the presence of the Src kinase inhibitor
SU 6656 (10 µM) or its vehicle in endothelium-disrupted arteries from CH
and control rats. Values are means ± SE n=4/group; *p<0.05 vs. control.
#p<0.05 vs. CH vehicle.
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Figure 39. CH-dependent enhanced vasoconstriction to ET-1 requires
EGFR.
Vasoconstrictor responses to ET-1 in pressurized, Ca2+
permeabilized, endothelial disrupted pulmonary arteries from CH and
control rats in the presence of the specific EGFR inhibitor, AG 1478 (1 µM),
or vehicle. Values are means ± SE n=4-6/group; *p<0.05 vs. control.
#p<0.05 vs. CH vehicle.
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Figure 40. Src kinases contribute to enhanced ET-1-mediated
vasoconstriction and Ca2+ sensitization following CH. Vasoconstrictor
responses to ET-1 in pressurized, Ca2+ permeabilized, endothelial
disrupted pulmonary arteries from CH and control rats in the presence of
SU 6656 (10 µM), or its vehicle. Values are means ± SE n=4/group;
*p<0.05 vs. control. #p<0.05 vs. CH vehicle.

91

Figure 41. O2- production induced by ET-1 in PASMCs from CH rats
requires EGFR. Digitally inverted representative images and mean
fluorescence intensity (MFI) of DHE fluorescence in thresholded images of
PASMCs from CH and control rats. Cells were treated with vehicle, ET-1
(10-8 M) and ET-1 plus the EGFR inhibitor AG 1478. Values are means ±
SE n=4-7/group. *p<0.05 vs. vehicle. #p<0.05 vs. CH vehicle. τp<0.05 vs.
CH ET-1.
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Vasoconstrictor responses to KCl in pressurized, Ca2+ permeabilized,
endothelial disrupted pulmonary arteries from CH and control rats in the

To further evaluate to role of Src kinases in enhanced vasoconstriction
following CH, we measured basal and ET-1 stimulated Src kinase activity in
pulmonary arterial homogenates from CH and control rats. No statistically
significant differences were detected in basal Src activity (Fig. 42). However,
following ET-1 stimulation, Src kinase phosphorylation (indicative of activity) was
greater in CH arteries compared to controls. No differences were detected in
total Src kinase expression (Fig. 43).
Mechanisms of EGF-Induced Vasoconstriction
To further characterize the role of EGFR in this response,
nonpermeabilized pulmonary arteries from CH and control animals were
stimulated with increasing concentration of EGF to directly activate EGFR.
Interestingly, EGF caused a robust vasoconstriction in arteries from CH rats,
while having little effect in control arteries (Fig 44A). There was no significant
Ca2+ increase associated with the EGF-induced vasoconstriction, suggesting a
role for Ca2+ sensitization in this response (Fig 44B).
We next sought to determine if EGF causes EGFR dependent constriction
in arteries from CH rats through a similar signaling cascade that mediates
enhanced reactivity to KCl and ET-1 and facilitates the development of basal
tone. Both ROK inhibition (Fig 42A) and NOX 2 inhibition (Fig 42B) prevented
vasoconstriction to EGF in pulmonary arteries from CH rats. Furthermore, AG
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Figure 42. Src tyrosine 416 phosphorylation is induced by ET-1 in
arteries from CH rats.
Representative Western blots and mean
densitometric data for phosphorylated (active) Src normalized to total Src
in pulmonary arterial homogenates from control and CH intrapulmonary
arteries. Phosphorylated and total Src were measured under baseline and
KCl-stimulated (60 mM) conditions. Values are means ± SE n=4/group.
*p<0.05 vs. control ET-1.
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Figure 43. CH does not alter Src kinase expression is in pulmonary
arteries. Mean densitometric data for Src kinase expression normalized to
β-actin expression in intrapulmonary arteries from normoxic and CH rats.
Values are means± SE n=8/group; there were no significant differences.
Vasoconstrictor responses to KCl in pressurized, Ca2+ permeabilized,
endothelial disrupted pulmonary arteries
from CH and control rats in the
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presence of the specific NOX2 inhibitor, gp91ds-tat (50 µM), or its
scrambled control peptide. Values are means±SE n=4-5/group; *p<0.05
vs. control.#p<0.05 vs. CH vehicle.

Figure 44. EGF causes pulmonary vasoconstriction only in arteries from CH
rats. A) Vasoconstrictor and B) vessel wall Ca2+ responses to EGF in
pressurized, endothelium disrupted pulmonary arteries from CH and control rats.
Values are means ± SE n=4-5/group; *p<0.05 vs. control.
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Figure 45. EGF-induced vasoconstriction of pulmonary arteries from
CH rats requires ROK and NOX 2. Vasoconstriction to EGF in arteries
from CH and control rats in the presence of a ROK inhibitor (HA-1077,
10μM;A), the NOX 2 inhibitory peptide (gp91ds-tat, 50 μM; B), or their
respective vehicles. All arteries were endothelium-disrupted. Values are
means ± SE n=4-5/group; *p<0.05 vs. control. #p<0.05 vs. CH vehicle.
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1478 prevented EGF-induced vasoconstriction in arteries from CH rats (Fig.
46A), confirming a role for EGFR in this response. Finally, we wished to examine
the role of Src kinases in EGF-induced vasoconstriction in CH arteries to
determine if Src kinases signal proximally or distally to EGFR. Src inhibition was
without effect on either group of arteries suggesting that Src kinases are not
involved in EGF-induced vasoconstriction (Fig. 46B).
Role of matrix metalloproteinases in enhanced pulmonary vasoconstriction
following CH
As experimental evidence exists for Src kinase to active EGFR through
both MMP-dependent (18; 236; 263) and MMP-independent mechanisms (87;
146; 190; 234), we initially examined vasoconstrictor responses to ET-1 in the
presence of a general MMP inhibitor, GM6001, in Ca2+ permeabilized pulmonary
arteries. We found the MMP inhibition prevented the effect of CH to augment
vasoconstriction to ET-1 and further normalized responses between groups (Fig.
47).
As members of the gelatinase family of MMPs are likely mediators of this
response (see Introduction page 22), we further investigated the roles of the
gelatinases MMP 2 and MMP 9 in enhanced vasoconstriction to ET-1 following
CH. MMP 2 inhibition with MMP 2 inhibitor 3 prevented enhanced
vasoconstriction to ET-1 in CH arteries and resulted in a similar degree of
vasoconstriction in arteries from each group (Fig. 48). Consistent with previous
results (124; 131; 240), we observed an effect of CH to increase MMP 2
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Figure 46. EGF-dependent vasoconstriction following CH requires
EGFR but not Src kinases. Vasoconstrictor responses to EGF in
pressurized, endothelium disrupted pulmonary arteries from CH and
control rats. Experiments were performed in the presence or absence of
(AG 1478, 1μM;A) and (SU 6656, 10μM; B). Values are means ± SE n=45/group; *p<0.05 vs. control. #p<0.05 vs. CH vehicle.
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Figure
47.
General
MMP
inhibition
prevents
augmented
vasoconstriction to ET-1 following CH. Vasoconstrictor responses to
ET-1 in pressurized, Ca2+ permeabilized, endothelium disrupted pulmonary
arteries from CH and control rats in the presence of GM6001 (15 µM), or
vehicle. Values are means ± SE n=4-5/group; *p<0.05 vs. control.
#p<0.05 vs. CH vehicle.
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Figure 48. MMP2 is required from enhanced vasoconstriction to ET-1
following CH. Vasoconstrictor responses to ET-1 in pressurized, Ca2+
permeabilized, endothelial disrupted pulmonary arteries from CH and
control rats in the presence of the MMP 2 inhibitor, MMP 2 inhibitor 3 ( AP100, 100 nM), or vehicle. Values are means ± SE n=4/group; *p<0.05 vs.
control. #p<0.05 vs. CH vehicle.
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expression (Fig. 49). MMP 9 inhibition with MMP 9 inhibitor 2 attenuated
vasoconstriction at the highest concentration of ET-1 (Fig. 50), but responses in
CH arteries remained augmented compared to control arteries. No significant
differences in MMP 9 expression were detected between groups (Fig. 51).
ADAM-17 is also capable of EGF shedding (195), and has an established
role in ET-1 signaling (234). We tested the role of ADAM-17 in enhanced ET-1
induced vasoconstriction with the ADAM-17 inhibitor TAPI-1. TAPI-1 slightly
attenuated the response to ET-1 at the highest concentration of ET-1 (10-7 M),
but augmented vasoconstriction to ET-1 following CH persisted (Fig. 52).
Furthermore ADAM-17 expression was unaltered following exposure to CH (Fig.
53).
Role of ETR in metabotropic transduction of membrane depolarization and
increased intraluminal pressure to enhanced vasoreactivity following CH
We next tested the hypothesis that ETR couple membrane depolarization
and vessel wall stretch to EGFR-mediated calcium sensitization and
vasoconstriction in arteries from CH rats. However, combined inhibition of ETA
and ETB receptors with BQ-123 and BQ-788 (10 µM each) was without effect on
either KCl-dependent vasoconstriction (Fig. 54) or basal tone (Fig. 55) in arteries
from CH rats.
Contribution of EGFR to CH-induced PH
To evaluate the role of EGFR signaling in the development of CH-induced
PH, we treated animals daily for four weeks with an EGFR inhibitor, gefitinib (30
mg/kg/day) or vehicle pills administered orally. Animals exposed to CH had

102

Figure 49. MMP2 expression is increased in arteries from CH rats.
Western blots and mean densitometric data for MMP 2 in intrapulmonary
arteries from normoxic and CH rats. Values are means ± SE n=4/group;
*p<0.05 vs. control.
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Figure 50. MMP 9 does not contribute to augmented vasoconstriction
to ET-1 following CH. Vasoconstrictor responses to ET-1 in pressurized,
Ca2+ permeabilized, endothelium disrupted pulmonary arteries from CH
and control rats in the presence of the MMP 9 inhibitor, MMP 9 inhibitor 2
(10 µM), or vehicle. Values are means± SE n=4/group; *p<0.05 vs. control.
#p<0.05 vs. CH vehicle.

Vasoconstrictor responses to KCl104
in pressurized, Ca2+ permeabilized,
endothelial disrupted pulmonary arteries from CH and control rats in the
presence of the specific NOX2 inhibitor, gp91ds-tat (50 µM), or its
scrambled control peptide. Values are means±SE n=4-5/group; *p<0.05

Figure 51. MMP9 expression is not altered by CH. Western blots and
mean densitometric data for MMP 9 in intrapulmonary arteries from
normoxic and CH rats. Values are means ± SE n=4/group; no significant
differences were detected.
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Figure 52.
ADAM-17 inhibition does not prevent augmented
vasoconstriction to ET-1 following CH. Vasoconstrictor responses to
ET-1 in pressurized, Ca2+ permeabilized, endothelium disrupted pulmonary
arteries from CH and control rats in the presence of the ADAM-17 inhibitor,
TAPI-1 (10 µM) or vehicle. Values are means ± SE n=4-5/group; *p<0.05
vs. control. #p<0.05 vs. CH vehicle.
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Figure 53. ADAM-17 expression is not altered by CH. Western blots
and mean densitometric data for ADAM-17 in intrapulmonary arteries from
normoxic and CH rats. Values are means ± SE n=4/group; no significant
differences were detected.

Vasoconstrictor responses to KCl107
in pressurized, Ca2+ permeabilized,
endothelial disrupted pulmonary arteries from CH and control rats in the
presence of the specific NOX2 inhibitor, gp91ds-tat (50 µM), or its
scrambled control peptide. Values are means±SE n=4-5/group; *p<0.05

Figure 54. ETR signaling does not contribute to vasoconstriction to
KCl following CH. Vasoconstrictor responses to KCl in pressurized, Ca2+
permeabilized, endothelium disrupted pulmonary arteries from CH and
control rats in the presence of BQ 123 and BQ 778 (10 µM each). Values
are means ± SE n=4-5/group. *p<0.05 vs. control
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Figure 55. ETRs do not contribute to CH-dependent basal tone. Basal
arterial tone in small pulmonary arteries from CH rats in the presence or
absence of BQ 123 and BQ 778 (10 µM each). Values are means ± SE
n=4-5/group. No significant differences.
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reduced body weight (BW) compared to normoxic rats (Table 1). Treatment with
the EGFR inhibitor had no effect of body weight in either CH or control animals.
We additionally measured hematocrit in these animals and observed that CHdependent polycythemia does not require EGFR (Fig. 56).
Previous studies have implicated EGFR as a contributing factor to
monocrotaline-induced vascular remodeling in rats (42). Our results demonstrate
that the EGFR inhibitor gefitinib attenuated, but did not prevent vascular
remodeling following CH (Fig 57A and 57B). Gefitinib also reduced the
increased muscularization of small (<20 μm) pulmonary arteries associated with
CH (Fig. 58).
We observed increased RV weight, RV/BW (Table 1), and RV/LV+S ratios
(Fig. 59) in CH rats compared to controls in both vehicle and gefitinib treated
animals. However, gefitinib treated CH animals displayed a significantly lower
RV/LV+S than rats treated with vehicle pills suggesting a role for EGFR in right
ventricular hypertrophy. LV+S/BW ratios were not significantly different between
groups (Table 1).
In animals treated with vehicle pills, we observed a significant increase in
peak right ventricular pressure associated with CH (Fig. 60 A). EGFR inhibition
attenuated RVSP in rats exposed to CH, but not controls. However, even in the
presence of EGFR inhibition, CH RVSPs were elevated compared to controls.
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Table 1. Body weight (BW) and ventricular weight ratios for animals treated chronically
with an EGFR inhibitor.
Treatment

BW (g)

RV (mg)

LV+S/BW (mg/g)

RV/BW (mg/g)

Control Vehicle

372 ± 4

0.21 ± 0.01

2.03 ± 0.08

0.57 ± 0.02

CH Vehicle

303 ± 4*

0.33 ± 0.02*

1.98 ± 0.07

1.08 ± 0.06*

Control Gefitinib

360 ± 4

0.19 ± 0.01

2.07 ± 0.09

0.52 ± 0.02

CH Gefitinib

306 ± 5*

0.27 ± 0.02*#

2.21 ± 0.05

0.87 ± 0.06*#

Values are means  SE n=5 rats/group. * P < 0.05 vs. respective control. # P < 0.05 vs.
CH vehicle. n=5/group
RV, right ventricle wt.; T, total ventricle wt.; LV+S, left ventricle plus septum wt.
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Figure 56. CH-dependent polycythemia is not mediated by EGFR.
Hematocrit (%) from rats exposed to 4 weeks of CH or normoxia and
administered daily gefitinib and vehicle pills. Values are means ± SE
n=5/group. *p<0.05 vs. control.
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Figure 57. EGFR contributes to CH-induced pulmonary arterial
remodeling. Representative images and arterial wall thickness (% outer
diameter) of pulmonary arteries with diameters of <50 µm (A) and 50-100
µm (B) from CH and control rats administered daily gefitinib (30mg/kg/day)
or vehicle pills. Values are mean ± SE n=5/group. *p<0.05 vs. control.
#p<0.05 vs. CH vehicle.
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Figure 58. EGFR contributes to CH-dependent increases in the
incidence of fully muscularized small pulmonary arteries. Numbers of
fully muscularized arteries (0-20 µm) from 20 images/section. Values are
mean ± SE n=5/group. *p<0.05 vs. control. #p<0.05 vs. CH vehicle.
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Figure 59. EGFR contributes to CH-induced right ventricular
hypertrophy. RV/LV+S ratios from CH and control rats treated chronically
with the EGFR inhibitor gefitinib (30 mg/kg/day), or vehicle pills. Values
are means ± SE n=5/group. *p<0.05 vs. control. #p<0.05 vs. CH vehicle.
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Similar findings were observed for mean right ventricular systolic pressures
(Fig.60B). Heart rates were not significantly different between groups (control
vehicle = 319 ± 7, CH vehicle = 349 ± 6, control gefitinib = 326 ±11, and CH
gefitinib = 354 ± 15, n=5/group).
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Figure 60. EGFR contributes to elevated right ventricular systolic
pressure following CH. Peak (A) and mean (B) right ventricular
pressures from anesthetized CH and control rats treated chronically with
the EGFR inhibitor gefitinib (30 mg/kg/day), or vehicle pills. Values are
means ± SE n=4-5/group. *p<0.05 vs. control. #p<0.05 vs. CH vehicle.
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Aim 2 Major Findings



EGFR is required for the development of enhanced vasoconstriction to ET-1
and KCl and pulmonary basal tone following CH (Figs. 31, 37, and 39).



Depolarization-induced O2- generation in pulmonary arteries from CH rats
requires EGFR (Fig. 32).



EGFR activity is increased by KCl in CH arteries, but not controls (Fig. 34).



Src family tyrosine kinases are necessary for pressure-dependent basal tone,
enhanced vasoconstriction to KCl, and augmented vasoreactivity to ET-1
following CH (Figs. 36, 38, and 40).



Src kinase activity is increased by CH in ET-1 treated arteries, without
changes in Src kinase expression (Fig. 42).



CH induces vasoconstrictor responsiveness to EGF through an EGFRmediated Ca2+ sensitization mechanism involving NOX2 and ROK (Figs. 46
and 47). However, Src kinases do not appear to be involved in this response
(Fig. 48).
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MMPS are important mediators of enhanced ETR signaling following CH (Fig.
47). MMP 2, but not MMP 9 or ADAM-17, is required for enhanced
vasoconstriction to ET-1 in hypertensive arteries (Figs. 48, 50, and 52).



ETRs do not function as metabotropic mediators of pressure-dependent or
depolarization-induced tone following CH (Figs. 54 and 55).



EGFR contributes to CH-dependent vascular remodeling (Fig. 57), right
ventricular hypertrophy (Fig. 59), and increases in RVSP (Fig. 60).
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SPECIFIC AIM 3
Assess the contribution of pressure-dependent and ET-1-induced
membrane depolarization to augmented pulmonary vasoconstrictor reactivity
following CH.
Hypothesis:
We hypothesize that CH increases vasoconstrictor responsiveness by
coupling stretch and ET-1-mediated VSM membrane depolarization to
myofilament Ca2+ sensitization.
Contribution of membrane depolarization to CH-dependent basal tone.
Increases in intraluminal pressure could result in basal tone via activation
of stretch-activated ion channels that results in membrane depolarization. To
test the possibility that depolarization contributes to the development of pressuredependent pulmonary arterial tone, we permeabilized arteries to K+ with
valinomycin in combination with 16 mM extracellular K+ to clamp membrane
potential at ~60 mV [approximate membrane potential of a control artery under
baseline conditions (12 mmHg)]. Valinomycin treatment blocked the pressuredependent depolarization in both CH and control arteries (Fig. 61), and further
prevented CH-dependent depolarization at each pressure tested (12 and 35
mmHg). Valinomycin diminished the development of tone in arteries from CH
rats (Fig. 62) without altering vessel wall Ca2+ in arteries from either group (Fig.
63).
Additional protocols evaluated pressure-dependent responses in
nonpermeabilized arteries from each group in the presence or absence of the
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Figure 61.
Valinomycin/16 mM KCl prevents CH-and pressuredependent membrane depolarization. Sharp electrode membrane
potential measurements in isolated endothelium-disrupted pulmonary
arteries from CH and control rats under baseline (12 mmHg) and 35 mmHg
pressures. Experiments were performed in the presence/absence of
valinomycin/16 mM KCl. Values are means ± SE n=4/group. *p<0.05 vs.
control. #p<0.05 vs. CH vehicle 12 mmHg. τp<0.05 35 mmHg vs. 12
mmHg.
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KATP activator pinacidil (100 μM) pinacidil to hyperpolarize VSM membrane
potential. Experiments were performed in the presence of the L-type Ca2+
channel inhibitor diltiazem to prevent possible effects of pinacidil to reduce
vascular smooth muscle Ca2+. Pinacidil caused membrane hyperpolarization in
each group, but did not prevent depolarizing influences of either CH or pressure
(Fig. 64). Consistent with a role for VSM membrane depolarization in pressuredependent tone following CH, pinacidil attenuated this response in arteries from
CH rats (Fig. 65A) without altering vessel wall Ca2+ (Fig. 65B).

Role of membrane depolarization in receptor-mediated vasoconstriction
following CH.
ETR stimulation could also lead to membrane depolarization (248). We
tested the possibility that membrane depolarization contributes to enhanced
vasoconstriction to ET-1 following CH similar to Aim 3.1 using valinomycin and
16 mM KCl to set membrane potential at ~60 mV in Ca2+ permeabilized arteries.
Resting membrane potential was depolarized in CH arteries compared to
controls consistent with our other findings (Figs. 61 and 64). Interestingly, while
ET-1 caused a slight depolarization in control arteries (Fig. 66), there was no ET1 dependent depolarization in the CH arteries. Valinomycin/16 mM KCl
prevented these depolarizing effects of CH and ET-1, resulting in similar
membrane potential between groups. However, in contrast to effects of
valinomycin to prevent pressure-dependent tone in CH arteries (Fig. 62),
normalizing membrane potential between groups was without effect on
vasoreactivity to ET-1 in vessels from either CH or control arteries (Fig. 67).
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Figure 62. Membrane depolarization is necessary for CH-dependent
basal tone. Basal tone measurements in isolated endothelium-disrupted
pulmonary arteries from CH and control rats. Experiments were performed
in the presence/absence of valinomycin/16 mM KCl. Values are means ±
SE n=4/group. *p<0.05 vs. control.
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Figure 63. Vessel wall Ca2+ is not altered by valinomycin. Fura-2
fluorescence measurements in isolated endothelium-disrupted pulmonary
arteries from CH and control rats. Experiments were performed in the
presence/absence of valinomycin/16 mM KCl. Values are means ± SE
n=4/group. No significant differences were detected.
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Figure 64. Pinacidil hyperpolarizes membrane potential in arteries
from control and CH rats. Sharp electrode measurements of membrane
potential at 5 and 35 mmHg in endothelium disrupted pulmonary arteries in
the presence of diltiazem (50 µM) or diltiazem and pinacidil (100 µM).
Values are means ± SE n=4/group. Values are means ± SE n=4/group.
*p<0.05 vs. control. #p<0.05 vs. CH vehicle 12 mmHg. τp<0.05 35 mmHg
vs. 12 mmHg.
.
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Figure 65.
Membrane depolarization contributes to basal tone
following CH. Pressure dependent tone responses (A) and vessel wall
Ca2+ (B) in arteries treated with diltiazem (50 µM) or diltiazem and pinacidil
(100 µM). Values are means ± SE n=4/group. *p<0.05 vs. control.
#p<0.05 vs. CH vehicle.
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Figure 66. Valinomycin prevents CH- and ET-1 dependent membrane
depolarization. Sharp electrode measurements of membrane potential in
response to ET-1 in pressurized, Ca2+ permeabilized, endothelium
disrupted pulmonary arteries from CH and control rats in the presence of
valinomycin or vehicle. Values are means ± SE n=4-5/group *p<0.05 vs.
control. #p<0.05 vs. CH vehicle. τp<0.05 ET-1 vs. 12 vehicle.
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Figure 67. Augmented ET-1 dependent vasoconstrictor reactivity
following CH is not dependent on membrane depolarization.
Vasoconstrictor responses to ET-1 in pressurized, Ca2+ permeabilized,
endothelium disrupted pulmonary arteries from CH and control rats in the
presence of valinomycin or vehicle. Values are means ± SE n=4/group.
*p<0.05 vs. control.
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Aim 3 Major Findings


Membrane permeabilization to K+ prevents CH-induced and pressuredependent VSM membrane depolarization in small pulmonary arteries (Figs.
61 and 65).



Membrane depolarization is important for the development of CH-dependent
basal tone (Fig. 61).



ET-1 caused modest depolarization in control arteries, but not in arteries from
CH rats (Fig. 66). This response to ET-1 was prevented my membrane
permeabilization to K+.



Augmented ET-1 dependent vasoconstrictor reactivity following CH is not
dependent on membrane depolarization (Fig. 67).
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Chapter 4 - Discussion
The overall objective of this project was to determine mechanisms by
which CH exposure results in the development of basal pulmonary arterial tone,
enhanced vasoconstrictor reactivity and associated PH. The major findings of
this project are that following CH: 1) NOX 2-derived ROS contribute to pressuredependent pulmonary arterial tone and enhanced vasoconstrictor
responsiveness to both depolarizing stimuli and ET-1 through myofilament Ca2+
sensitization; 2) EGFR is activated by these stimuli and activates Rac1 to
mediate these ROS-dependent vasomotor responses; 3) EGFR contributes to
CH-induced right ventricular hypertrophy, arterial remodeling and elevated
RVSP; 4) Src kinases signal upstream of EGFR to mediate pressure-dependent
tone and augmented depolarization- and ET-1-induced pulmonary
vasoconstrictor reactivity; 5) MMPs contribute to ligand-dependent EGFR
activation in response to these stimuli; and 6) membrane depolarization is
required for pressure-dependent basal tone but not enhanced ET-1 mediated
vasoconstrictor reactivity. Together, these findings demonstrate a novel signaling
pathway in pulmonary VSM involving Src kinases, MMPs, and EGFR-dependent
Rac1 activation that mediates NOX 2-induced myofilament Ca2+ sensitization,
basal pulmonary arterial tone and augmented vasoconstrictor sensitivity following
CH. These studies further support an important contribution of EGFR signaling
to the development of CH-induced PH.
Exposure to CH increases basal pulmonary arterial tone (27; 177; 304)
and augments vasoconstrictor sensitivity to both receptor mediated agonists (10;
109; 182) and depolarizing stimuli (26; 177). Although mechanisms involving
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enhanced Ca2+ influx may additionally contribute to greater pulmonary
vasoreactivity following CH (105; 135; 285), it is clear that myofilament
Ca2+sensitization mediated by ROK provides a major contribution to these
vasoconstrictor responses (26; 27; 109; 177; 295). Interestingly, the effect of
depolarization to activate RhoA in hypertensive pulmonary arteries occurs
through a mechanism that is independent of L-type Ca2+ channel stimulation or
global changes in VSM [Ca2+]i, but dependent on ROS (26). Basal tone and
enhanced vasoconstriction to ET-1 following CH are also mediated by
myofilament Ca2+ sensitization and ROS signaling (27; 109). However, neither
the enzymatic source of O2-, nor the signaling mechanisms linking depolarization,
ETR stimulation, and increases in intraluminal pressure to O2- generation had
been previously addressed.
ROS ANDNADPH OXIDASE
Endogenous ROS derived from various enzymatic sources and cell types
are widely considered to play a critical role in the pathogenesis of various forms
of PH, including CH-induced PH (34; 79; 182). The mechanisms by which ROS
contribute to PH are multifaceted with roles associated with both enhanced
vasoreactivity and vascular remodeling.
O2- and H2O2 are the primary ROS known to be involved in regulation of
pulmonary vascular tone. Our laboratory has previously reported effects of CH to
increased pulmonary arterial O2- generation (109; 184). Direct effects of both
H2O2 and O2- to promote VSM contraction through various second messenger
pathways have been observed (30; 122; 135), while a purported role for H2O2 to
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exhibit relaxant properties also exists (30). Our research suggests that O2mediates a contractile effect in pulmonary VSM through activation of RhoA
leading to ROK-induced myofilament Ca2+ sensitization (26; 109).
NADPH oxidases have been implicated in the development of pulmonary
hypertension (98; 138; 168), and thus represent a potential source of O2mediatingenhanced vascular tone following CH. In agreement with this possibility
is evidence that CH-mediated increases in pulmonary vasoreactivity, ROS
production, and PH are attenuated in mice deficient in the catalytic subunit of
NOX 2 (138). Additionally, NOX 2 contributes to impaired endotheliumdependent pulmonary vasodilatation in mice (70) and neonatal piglets (68) with
CH-induced PH. Furthermore, CH increases NOX-derived ROS production,
NOX 1 expression, and p67phox levels in the membrane fraction of small
pulmonary arteries from piglets, suggesting elevated NOX 1 activity in neonatal
PH (48; 68). NOX 4 gene and protein expression are also elevated following CH
exposure in murine pulmonary arteries and lung tissue (11; 168; 182), and are
similarly upregulated by CH in cultured human pulmonary endothelial cells (145).
However, the contribution of NOX 4 to the development of enhanced
vasoconstrictor reactivity remains poorly understood.
Our present findings implicate NOX 2 as a primary source of ROS
mediating enhanced pulmonary arterial constriction and Ca2+ sensitization
following CH (184). A role for NOX in augmented depolarization-induced
vasoconstriction following CH is evident by effects of apocynin to attenuate
vasoconstrictor responses to KCl in nonpermeabilized arteries and isolated lungs
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from CH rats, but not controls (184). This argument is further supported by
evidence from Ca2+ permeabilized arteries that nonspecific NOX inhibition with
apocynin or DPI attenuated both vasoreactivity and O2- generation in response to
KCl selectively in arteries from CH rats. Furthermore, NOX inhibition prevented
KCl-dependent increases in O2- production as measured by DHE fluorescence
(184). Similar results were observed using the selective NOX 2 inhibitor,
gp91ds-tat, which competitively inhibits p47phox binding to the catalytic subunit of
NOX 2, and thus prevents assembly of the active enzyme complex (41). This
effect of gp91ds-tat does not appear to occur though an alteration of membrane
potential, as this inhibitor did not affect membrane potential under baseline
conditions or following administration of 60 mM KCl in either CH or control
arteries. These data support a distinct contribution of NOX 2-derived O2- to
enhanced depolarization-induced vasoconstriction independent of changes in
global vessel wall [Ca2+]i following CH. Although, we cannot exclude the
possibility that localized, subsarcolemmal Ca2+ events contribute to the observed
responses, we are confident that, within the sensitivity limits of the system, global
[Ca2+]i is effectively clamped by ionomycin in this preparation. An additional
limitation of this system is the inability to selectively measure VSM [Ca2+]i, as
other cell types within the vascular wall (e.g., fibroblasts) likely contribute to the
fura 2 signal. Experiments with 2 photon microscopy (data not shown), suggest
that the majority of the fura 2 signal is localized to the VSM and that fura loading
is similar between CH and control arteries, although adventitial remodeling
resulting from CH exposure may increase the contribution of this layer to the
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overall fura 2 signal. Other cell types may additionally contribute to the DHE
signal in studies performed in isolated arteries.
Similar to previous findings (27), we observed the development of basal
tone with increasing intraluminal pressure in arteries from pulmonary
hypertensive rats, but not controls. We tested the role of NOX in this response
using the broad spectrum NOX inhibitor apocynin in nonpermeabilized arteries
and found that NOX inhibition prevented the development of tone in arteries from
CH rats. Selective NOX 2 inhibition with the gp91ds-tat peptide was also
sufficient to prevent the development of basal tone. gp91ds-tat similarly
prevented augmented vasoconstrictor reactivity to ET-1 in Ca2+ permeabilized
arteries. These findings suggest that similar to enhanced depolarization-induced
vasoconstriction, NOX 2 serves as the enzymatic source of O2- that mediates the
development of basal tone and agonist induced vasoconstriction through ROKdependent Ca2+ sensitization.
It is unlikely that greater basal and ET-1 (109) and depolarization (26; 184)
stimulated O2- production following CH are a function of increased arterial NOX 2
expression. We found no difference in NOX 2 catalytic subunit (gp91phox) protein
expression between arteries from CH and control rats, consistent with findings by
Lui et. al. which demonstrated no change in mRNA levels of gp91phox, p47phox,
p67phox, or Rac1 in a hypoxic murine model of pulmonary hypertension (138).
The lack of effect of NOX inhibition on vasoreactivity and O 2- levels in control
arteries suggests that CH facilitates a coupling of depolarization, membrane
stretch induced through increases in intraluminal pressure, and ETR stimulation
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to NOX 2 activation that is not present in the normal pulmonary circulation.
Nevertheless, we cannot exclude a possible contribution of altered expression of
other components of the NOX 2 complex to this response.
Another factor that may contribute to enhanced NADPH oxidase-derived
O2- following CH is increased NADPH production. Glucose-6-phosphate
dehydrogenase, the rate limiting enzyme in NADPH production, can contribute to
coronary artery smooth muscle contraction (83). Reports from Gupte et. al. (84)
have demonstrated that acute hypoxia can increase NADPH levels through
activation of glucose-6-phosphate dehydrogenase. It remains to be determined it
this effect persists with CH, but the increased NADPH substrate may further drive
the production of O2- following CH.
As NOX 2 expression was unaltered following CH, we sought to determine
if alterations in NOX 2 enzyme activation mediate the enhanced vascular tone
development following CH. Rac1 is an important mediator of NOX 1 and 2
activation (21; 38), and thus represents a potential signaling factor that links
membrane depolarization, intraluminal pressure, and ETR activation to
stimulation of NOX 2. Consistent with this possibility is evidence that
depolarization activates Rac1 and NOX in endothelial and macula densa cells
(32; 142; 158; 254). Here we demonstrate that KCl-mediated membrane
depolarization activates Rac1 selectively in arteries from pulmonary hypertensive
rats. Our findings that basal and KCl-mediated O2- generation and associated
vasoconstriction are diminished by NSC 2376 only in CH arteries further suggest
that Rac1 activation contributes to both elevated resting O 2- levels and
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depolarization-stimulated O2- production and vasoconstriction following CH.
Rac1 inhibition also prevented the development of CH-dependent basal tone and
enhanced vasoconstriction to ET-1. Combined, these data support a role for
Rac1activation as a critical signaling component leading to enhanced VSM Ca 2+
sensitization and vascular tone following CH.
It is additionally possible that the phosphorylation state of the NOX 2
components p47phox and p67phox is altered by CH, agonist signaling, increases in
intraluminal pressure, or membrane depolarization. Phosphorylation of these
subunits can also contribute to NOX activation (21; 38; 153). Recent evidence
also suggests that catalytic subunit modifications have the potential to alter
enzyme activity (264).
EGFR
The present studies additionally support a novel role for EGFR in the
development of CH-induced PH. Based on evidence that depolarization leads to
EGFR activation in PC12 cells (56; 318) and that membrane stretch stimulates
EGFR-dependent NOX activation in mesangial cells (314), we examined a role
for EGFR as a proximal mediator of depolarization-induced, Rac1-dependent,
NOX 2 activation in CH arteries. A role for EFGR in this response is supported
by our present findings that EGFR phosphorylation was induced by a
depolarizing stimulus only in CH arteries, and that selective EGFR inhibition
prevented effects of CH to augment both depolarization-induced vasoconstriction
and vascular O2- production. We additionally found that depolarization-mediated
Rac1 activation in intrapulmonary arteries from CH rats was prevented by AG
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1478, suggesting EGFR signals upstream of Rac1. Unlike responses to Rac1
and NOX 2 inhibition, inhibition of EGFR had no effect to reduce basal ROS
production in vessels from CH rats, suggesting that while EGFR is necessary for
KCl-mediated O2- production, CH elevates basal O2- levels through an EGFRindependent mechanism. Further supporting this line of thought is our
observation that basal levels of phosphorylated EGFR were unaltered following
exposure to CH.
We examined the role of EGFR in the development of pressure-induced
tone in arteries from CH rats. Both tested EGFR inhibitors prevented the
development of pressure-dependent tone in pulmonary arteries from CH animals.
EGFR inhibition also prevented the enhanced vasoreactivity to ET-1 in CH
arteries. Combined these findings suggest that enhanced vascular tone following
CH is mediated via EGFR-dependent NOX activation.
In contrast with our experiments in isolated arteries, we did not observe
significantly greater ROS production in PASMCs from CH rats compared to
controls. However, similar to effects of KCl in isolated arteries, ET-1 led to an
increase in ROS in PASMC from CH rats while having no effect in controls. This
ET-1-dependent ROS production was prevented by EGFR inhibition, further
supporting a role for EGFR in enhanced ROS-dependent vasoconstriction and
Ca2+ sensitization to ET-1 following CH. Although we cannot exclude the
possibility that other vascular cells contribute to this signaling pathway in vivo,
these findings in PASMC suggest that the cellular players in this response are
located in pulmonary VSM.
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While previous studies have observed a role for EGFR in monocrotalineinduced pulmonary hypertension (42; 162), the role of this receptor in mediating
CH-induced PH in rats had not previously been examined. We observed right
ventricular hypertrophy and elevated peak RVSPs in CH animals compared to
controls, both indicative of the development of PH. Daily treatment of animals
with an EGFR inhibitor, gefitinib (30mg/kg/day), attenuated both these indices of
PH. EGFR inhibition did not prevent CH-dependent or polycythemia, indicating
that EGFR does not play a role in this responses. Indeed there is no known role
for EGFR in HIF-1α-dependent erythropoiesis. Our findings contrast those in
mice where chronic EGFR inhibition did not significantly attenuate CH-dependent
RV hypertrophy, vascular remodeling, or increases in RVSP (42). One potential
explanation for the discrepancy between these findings is species differences.
Dahal and colleagues additionally found that EGFR expression was not altered in
lungs from idiopathic pulmonary hypertensive patients or animal models of
pulmonary hypertension (42), and they concluded that EGFR inhibition does not
likely have significant therapeutic potential. However, this study did not examine
EGFR activity, and our studies support a novel role for posttranslational
modifications of EGFR, not changes in expression, to mediate enhanced
vasoconstriction following CH.
EGFR has previously been implicated in pulmonary vascular remodeling
in both neonatal (247) and monocrotaline models of PH (42). We found that
EGFR inhibition attenuated the vascular remodeling in CH-induced PH and
decreased the muscularization of small pulmonary arteries. While the
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mechanisms that lead to EGFR-induced remodeling remain to be addressed, it is
possible that EGFR-dependent gene transcription is involved. NADPH oxidases
are enzymatic sources of ROS that contribute to the vascular remodeling
component of PH (11). Therefore in addition to mediation of enhanced vascular
tone development following CH, enhanced EGFR/NOX signaling in lungs from
CH animals also contributes to the vascular remodeling component of CHdependent PH.
To further characterize EGFR signaling following CH, we applied
increasing concentrations of EGF to isolated pulmonary arteries. Interestingly,
we observed vasoconstriction only in arteries from CH rats that was not
associated with a significant increase in vessel wall [Ca2+]i. Prevention of this
response with an EGFR inhibitor confirms that the effect of EGF in vessels from
CH rats is mediated through EGFR. This vasoconstriction was additionally
dependent on ROK and NOX 2 similar to the development of basal tone and
enhanced vasoconstriction following CH (184). These results suggest that an
alternative signaling pathway involving Src-dependent EGFR activation, unique
to the hypertensive pulmonary circulation, is unmasked or evoked by CH
exposure. It is possible that oxidative stress following CH facilitates this pathway
through oxidation of cysteine residues on EGFR leading to enzyme activation
(71; 277). However, it is additionally possible that CH alters the composition of
lipid signaling domains to permit EGFR signaling, as discussed in the following
section.
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While PKC-dependent NOX activation is an additional mechanism of O2generation (58), previous experiments from our laboratory demonstrated that
enhanced Ca2+ sensitization and vasoconstriction following CH are not
attenuated by general PKC inhibition (26; 109). Other HER family members,
besides EGFR (HER1), could also potentially contribute to this response. HER2
has been shown to form signaling complexes with EGFR (292; 317), and
dimerization with HER3 and HER4 can also occur (194). Therefore, CH may
facilitate coupling of these other HER family members with EGFR to mediate
enhanced vasoconstriction, although this possibility remains to be tested.
Signal Regulation by Lipid Domains
Regulation of EGFR by lipid rafts serves as an additional target for
investigation. Caveolin-1 (cav-1) is a critical structural component of lipid
domains known as caveolae. This protein contains an intracellular scaffolding
domain that additionally regulates the activity of various signaling pathways (36;
40; 134). Cav-1 phosphorylation facilitates EGFR (312) and NOX (314)
activation in response to membrane stretch and depolarization in mesangial
cells, while cav-1 has been implicated as a key regulator of metalloproteinasedependent EGFR transactivation (271). Our preliminary studies suggest a role
for cav-1 dysfunction in enhanced depolarization-induced vasoconstriction
following CH (Supplemental Figure 1, Appendix B) as a peptide consisting of the
cav-1 scaffolding domain (AP-Cav) was able to prevent augmented
vasoconstrictor reactivity to KCl following CH (187). Decreases in cav-1 protein
have been observed in humans with idiopathic PH and several models of PH (8;
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33; 101; 316), although Patel and colleagues found increased VSM expression of
cav-1 in idiopathic pulmonary arterial hypertension (202). Preliminary findings
from our laboratory demonstrated no effect of CH on either pulmonary arterial
cav-1 expression (assessed by Western blotting) or caveolae number (assessed
by electron microscopic analysis of lung sections) in rats (187). Therefore, cav-1
dysfunction in this setting is not likely a result altered expression, but rather a
change in cav-1 function that facilitates EGFR/NOX activation following CH.
Cholesterol is a key regulator of cav-1 expression and function (86; 171).
Preliminary findings by our group suggest that VSM membrane cholesterol is
decreased following CH (186). Interestingly, we found that EGF induced
vasoconstriction in CH arteries was attenuated by pretreatment with
supplemental cholesterol (Supplemental Figure 2), while enhanced
vasoconstriction to EGF was unmasked in control arteries treated with methyl-βcyclodextrin to reduce membrane cholesterol (Supplemental Figure 2). Although
supplemental cholesterol also diminished vasoconstriction to KCl in Ca2+
permeabilized pulmonary arteries from CH rats, enhanced vasoconstrictor
reactivity was not observed in arteries from control animals with reduced
membrane cholesterol (186). These findings suggest that the pathway linking
EGFR signaling to NOX-dependent ROS production is inhibited by cholesterol in
control arteries, and that decreased cholesterol in hypertensive animals
facilitates the activation of an EGFR/NOX 2 signaling axis. Furthermore, our
findings that vasoconstriction to EGF but not enhanced vasoconstriction to KCl
can be unmasked by cholesterol depletion in control arteries suggest that CH
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additionally facilitates signaling upstream of EGFR involving Src kinases and
MMPs.
Future studies will be necessary to elucidate that relative contribution of
membrane cholesterol and cav-1 to enhanced pulmonary vasoconstriction
following CH. Cav-1 has been shown to negatively regulate EGFR activation by
angiotensin II in aortic VSM (271), and NOX 1 co-localizes with cav-1 in VSM
(90). Recent findings by Chen et. al. implicate a direct role of cav-1 to regulate
NOX function (33). Alternatively, other reports suggest a direct role of membrane
cholesterol to regulate EGFR function (225). Cholesterol oxidation, potentially
through increases in oxidative stress associated with CH, can also result in cav-1
dysfunction (139). Therefore, as opposed to a decrease in total membrane
cholesterol, it is possible that an increase in oxidized cholesterol (not detected by
filipin fluorescence) facilitates activation of EGFR in arteries from pulmonary
hypertensive animals.
SRC FAMILY KINASES
Src family kinases are a large subgroup of non-receptor tyrosine kinases
including Src (c-Src), Yes, Fyn, Blk, Lyn, Hck, Yrs, Lck, and Fgr that have similar
functions and structures (201). mRNA for all nine of these kinases is expressed
in the pulmonary circulation (121). We investigated the hypothesis that Src
kinases mediate basal tone and enhanced depolarization and agonist-induced
vasoconstriction following CH due to evidence that Src kinases couple these
stimuli to EGFR activation (87; 146; 190; 314). Consistent with this hypothesis,
we found that Src kinase inhibition prevented pressure-induced tone, as well as
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enhanced vasoconstriction to KCl and ET-1 following CH, similar to effects of
EGFR, NOX 2 and Rac1 inhibition.
Our finding that Src kinase inhibition did not prevent EGF-induced
vasoconstriction in arteries from CH rats supports the hypothesis that Src
kinases activate EGFR in response to depolarization, membrane stretch or ET-1
stimulation. We observed no detectable difference in basal Src kinase activity in
pulmonary arterial homogenates of CH and control rats. In ET-1 stimulated
arteries, however, CH exposure led to an increase in phosphorylated Src kinase
at its activation residue, tyrosine 416 (232). Interestingly, Src phosphorylation
can also by induced in response to prostaglandin F2α (PGF2α) in the pulmonary
circulation (121), suggesting that other agonists coupled to GPCRs may also
activate Src kinase signaling.
Recent findings by Pullamsetti and colleagues support a novel role for Src
family kinases in the development of monocrotaline-induced pulmonary
hypertension (210). This study demonstrated that combined Src kinase/ plateletderived growth factor (PDGF) inhibition prevented vascular remodeling. Our data
provide novel insight into the signaling pathway involved in this response, and
define the role of Src in the vasoconstrictor component of PH. As Src kinases
represent a sizable family of proteins, elucidating the specific Src kinase(s)
involved, remains an area for future investigation. A likely candidate is c-Src,
since myogenic tone in systemic arteries requires c-Src (173), and c-Src has
been linked to depolarization-induced RhoA activation in mesangial cells (314).
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Src family kinases are important mediators of transduction of GPCR (147;
246) and mechanical (314) stimuli to EGFR activation. Src kinases can directly
activate EGFR via ligand-independent phosphorylation (18; 236; 263).
Additionally, Src kinases can also activate EGFR through ectodomain shedding
of transmembrane ligands into mature ligands via MMPs (146).
MMPs
Ligands for EGFR are expressed in VSM cells (51; 258). Our findings with
a general MMP inhibitor support a role for EGF or another growth factor shed by
MMPs to bind to and activate EGFR. Of the selective MMP inhibitors used in this
study, only MMP 2 inhibition restored vasoreactivity to ET-1 in CH arteries to the
level of controls. Furthermore, we detected increased MMP 2 protein levels in
CH arteries compared to controls. Conversely MMP 9 and ADAM-17 inhibition
did not normalize vasoconstriction to ET-1 between CH and control arteries,
although they did have a modest effect to attenuate pulmonary vasoreactivity to
ET-1 in arteries from CH rats.
One limitation of the current study is the limited selectivity of isoformspecific MMP inhibitors due to the structural similarity of these proteins. While
MMP-3 can also result in EGFR shedding (266), findings that MMP-3 expression
is decreased in pulmonary hypertension (131) suggest that this enzyme is not a
critical mediator of this response, although some contribution cannot be ruled
out. As MMPs are located in the extracellular space, the isolated vessel
preparation employed in this study could lead to the loss of extracellular MMPs.
This could provide one explanation for the observed results, and presents the
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possibility that alternative MMPs could have a role in this response in vivo. For
instance, ADAM-17 plays a crucial role in MMP-2 activation resulting in
angiotensin II-induced hypertension in the systemic circulation (189).
Hypoxia increases MMP-2 expression in a variety of cell types (2; 167;
305). MMP-14 (MT1-MMP) can activate MMP-2 at the cell surface (265), so
potential alterations in MMP-14 activity with CH could also contribute to this
pathway. Interestingly, ROS can increase both Src (75; 278) and MMP (274)
activity. Therefore, general oxidative stress associated with CH may facilitate
this signaling pathway.
Due to their ability to regulated MMPs and ADAMs (22; 77), TIMPs could
also be playing a role in this response. TIMPS inhibit MMPs by association and
chelating the catalytic zinc cofactor required for metalloproteinase activity (66;
78). Interestingly, increased MMP2 activity in pulmonary arteries from patients
with idiopathic pulmonary hypertension has been associated with TIMP
imbalance (131). Whether or not TIMPs play a role in the studied responses
remains to be established. However, even if they are not involved in this
response, they may provide a therapeutic tool in the treatment of PH due to their
ability to regulate MMP activity.
SIGNALING PATHWAY INTERACTIONS
Previous reports have demonstrated VSM membrane depolarization
associated with increases in intraluminal pressure in pulmonary arteries from
both CH and control rats (179), and ET-1-induced depolarization in PASMCs
from normotensive rats (248).These studies suggest a potential role for
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membrane depolarization to mediate the enhanced vasoconstrictor sensitivity to
these stimuli. Consistent with these earlier studies, we found that VSM cells in
CH arteries were depolarized compared to controls, and observed pressuredependent depolarization in arteries from both groups. We tested the possibility
that membrane depolarization contributes to pressure-dependent pulmonary
arterial basal tone by clamping membrane potential with valinomycin and 16 mM
KCl or by hyperpolarizing the membrane potential through activation of KATP
channels with pinacidil. The valinomycin treatment prevented CH- and pressuredependent depolarization and prevented the development of basal pulmonary
arterial tone. These findings suggest that basal tone following CH is mediated
through depolarization. Activation of stretch-activated cation channels
represents a likely possibility as to how this stretch-induced depolarization
occurs. Transient receptor potential channels, for instance, regulate myogenic
tone via stretch-dependent depolarization in systemic arteries (298). However,
depolarization alone does not account for the effect of CH, as control arteries
depolarized with KCl do not demonstrate Src/EGFR/NOX-dependent
vasoconstriction. Therefore, while depolarization is an important stimulus
mediating basal tone following CH, CH has some other effect that allows for
Src/EGFR/NOX activation in response to a depolarizing stimulus. While this
change may involve an alteration in lipid signaling domains (186), CH seems to
facilitate the coupling of membrane depolarization to Src dependent EGFR
activation, a signaling pathway that does not exist in controls. One possibility as
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to how this might occur is through metabotropic signaling by voltage sensitive Ltype VGCC which can activate ROK (67).
We also examined the role of membrane depolarization in vasoconstrictor
responses to ET-1. Whereas we observed no effect of ET-1 to elicit VSM cell
depolarization in CH arteries, we did detect a modest depolarizing response to
ET-1 in control arteries. This is consistent with findings demonstrating a
depolarizing effect of ET-1 in isolated VSM cells from rat pulmonary arteries and
no effect of ET-1 to elicit depolarization in PASMCs from CH rats (248). In
addition, depolarization does not appear to contribute to ET-1-dependent Ca2+
sensitization following CH as vasoconstrictor responses to ET-1 in Ca2+
permeabilized arteries from CH rats were elevated compared to control arteries
even when membrane potential was maintained at ~-60 mV.
Although the present study provides insights regarding the signaling
mechanisms that link vessel wall stretch, membrane depolarization and ETR
stimulation to enhanced vasoreactivity following CH, further studies are
necessary to elucidate how these various stimuli result in Src kinase activation.
As GPCRs are capable of Src kinase activation (148), enhanced vasoconstriction
to ET-1 following CH may result from direct activation of Src kinases via ETR.
Due to the ability of GPCRs to activate Src kinases in COS-7 cells (148),
and findings that depolarization (141; 154) and mechanical stimuli (113; 161) can
activate GPCRs, we wished to determine if metabotropic signaling of ETR couple
membrane depolarization and mechanical stimuli mediating basal tone to
Src/EGFR/NOX 2 activation. Combined ETAR and ETBR inhibition did not
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prevent augmented vasoconstriction to KCl in CH arteries, nor was it able to
prevent the development of pressure-dependent tone. These results suggest
that basal tone and enhanced vasoconstriction to depolarizing stimuli occur
independent of ETR activation.
Another potential location of Src signaling is in integrin complexes through
detection of membrane stretch (205; 223). Changes in various integrin subunit
expression levels have been observed in both CH and monocrotaline-induced
PH (282), and mechanical stretch can result in integrin dependent EGFR
activation (120).While membrane stretch could directly activate Src kinases
through signaling locations such as integrin complexes (205; 223), it is more
likely that Src activation occurs through pressure-dependent membrane
depolarization. This is supported by our findings that basal tone requires
membrane depolarization. The mechanism by which membrane depolarization
leads to Src activation is not clear. Potential candidates include metabotropic ion
channel signaling (67), G-protein coupled receptors (other than the ET-1
receptor, Fig. 45) (141; 154), and voltage sensitive phosphatases (172).
Interestingly, persistent vasoconstrictor responses to KCl and ET-1 were
observed in Ca2+ permeabilized arteries from both CH and control rats after
inhibition of NOX, Rac1, EGFR, or Src in arteries from both groups. Previous
findings have demonstrated that a portion of this remaining ET-1-dependent
vasoconstriction is mediated by ROK (109). Our observations that NOX, EGFR,
and Src inhibition had no effect in control arteries suggest that ET-1 stimulation
can lead to ROK-dependent vasoconstriction through additional mechanisms.
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Neither inhibition of ROK and PKC, nor scavenging of O2-significantly attenuated
the remaining vasoconstriction to KCl (26). Although the mechanism of this
residual vasoconstriction is unknown, it is possible that a Ca2+-independent
myosin light chain kinase, such as integrin linked kinase (47) or ZIP kinase (181),
contributes to this response.
The presence of basal tone in CH but not control arteries could be a
confounding factor in our findings. Although little if any tone development occurs
in arteries from CH rats at intraluminal pressures of 12 mmHg used for
vasoreactivity studies (Fig. 25), it is possible that any drug-induced increases in
basal tone could limit subsequent vasoconstrictor responses to KCl or ET-1 due
to a ceiling effect (i.e. when vessel diameter approaches the limit of detection).
However, vessel diameters were similar between groups in the presence and
absence of inhibitors, suggesting that these inhibitors did not produce substantial
changes in basal tone (Appendix C). Tone in Ca2+ permeabilized arteries (300
nM Ca2+) tended to be greater in vessels from CH rats compared to controls, but
there were no apparent effects of inhibitors to alter tone in these arteries
(Appendix C).
Approaches that assess organ regulation independent of the whole animal
have several limitations. Living organisms are complex functional systems. The
present study relied heavily on isolated vessel approaches in endothelium
disrupted arteries. In vivo there are a variety of other factors, such as NO, AVP,
and ET-1, released from the surrounding lung, the endothelium, and sources
other than the lung that can alter the level of tone within the pulmonary
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circulation. Endothelium-derived ROS contribute to regulation of pulmonary
vascular smooth muscle tone (107), and the present study does not examine this
source of ROS. Pulmonary arteries in the whole animal are surrounded by the
structure of the lung. This structure may limit the distension of arteries (Fig. 7) in
response to increases in intraluminal pressure in vivo. Additionally, our studies
focus on only one branch of the arterial tree, making it somewhat difficult to
extrapolate our findings to the whole pulmonary circulation. However, previous
findings from our laboratory demonstrate that enhanced vasoreactivity to KCl in
isolated saline perfused lungs requires O2- and ROK similar to the pathway
studied in isolated vessels (26). This supports a role for the present findings in
the intact pulmonary circulation.
PHYSIOLOGICAL SIGNIFICANCE
CH, associated with residence at high altitude and chronic obstructive
pulmonary diseases, is a pathophysiological stimulus that leads to PH and right
heart failure in severe cases of lung disease. Although PH is a multifaceted
disease with many contributing factors, increasing evidence suggests that
mechanisms of ROK-mediated Ca2+ sensitization are important in this disease
(177), and that inhibition of this response provides a promising avenue of
therapeutic potential in the treatment of PH (12). The ability to understand the
signaling pathways that mediate this response may provide the potential for
alternative treatments for PH. Findings by this study and others (42; 162) suggest
that EGFR inhibition, through attenuations in remodeling and vasoconstriction,
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may provide a therapeutic target for the treatment of PH. Src kinases, MMPs,
and NOX 2 are also potential drug targets.
Vasoconstriction to other agonists besides ET-1 is augmented following
CH. Increased vasoreactivity to PGF2α, the thromboxane analogue U-46619, 5HT, and norepinepherine has been observed in the hypertensive pulmonary
circulation (159; 207; 290). CH may also couple these other GPCRs to ROKdependent Ca2+ sensitization via the mechanisms studied. Increased production
of several agonists, such as ET-1 (4; 49), 5-HT (63), and thromboxanes (123) in
the setting of PH could make this pathway more relevant. Furthermore, any
stimuli that evoke membrane depolarization may also be capable of activating
this Src/EGFR/NOX pathway. This signaling pathway may also be relevant in
the normoxic pulmonary circulation. Vasoconstriction to PGF2α in pulmonary
arteries also requires ROK-mediated Ca2+ sensitization (121). Interestingly, this
vasoconstriction also involved Src kinases.
The basal tone in pulmonary arteries from CH rats observed by this study
and previous findings from our laboratory (27) suggest that this response is
markedly different compared to systemic vessels. In systemic vessels, myogenic
tone is characterized by a passive distention to pressure followed by active
constriction mediated by calcium influx (45; 198). In contrast, tone development
in the pulmonary circulation is not associated with a secondary constriction, but
rather a limiting of the distension that occurs. Where pressure dependent tone in
the systemic circulation regulates blood flow in response to changes in blood
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pressure (45), the tone in pulmonary arteries appears to be pathological in
nature.
Depolarization stimulates ROS production in a variety of cell types
including the endothelium, neurons, and macula densa cells (1; 32; 126; 143;
239; 254). A similar Src/EGFR/NOX signaling pathway to the one in the present
study has been identified in renal mesangial cells (314). Alterations in Src and
EGFR signaling are observed in numerous forms of cancer (117). A wide variety
of EGR mutants have been observed in tumors with functional consequences
(94; 127). Therefore, the relevance for the findings in the current study are not
limited to the pathology of PH, but may have broader implications for regulation
of contraction, proliferation and apoptosis in other forms of lung injury,
cardiovascular disease, and tumorigenesis associated with hypoxia and oxidative
stress.
CONCLUSIONS
In conclusion, we have identified a unique signaling pathway in pulmonary
vascular smooth muscle involving Src-dependent, EGFR-induced Rac1 and NOX
2 activation that couples membrane depolarization and ETR stimulation to
myofilament Ca2+ sensitization and ROK-dependent vasoconstriction (Fig. 68).
Increases in intraluminal pressure appear to activate this pathway through
stretch-dependent membrane depolarization. Furthermore, whereas this
signaling pathway does not exist in the normotensive pulmonary circulation, it is
induced by long-term hypoxia, and may provide a basis for understanding
mechanisms of VSM Ca2+ sensitization and vasoconstriction that contribute to
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CH-induced PH. Finally, our studies in animals treated chronically with an EGFR
inhibitor support a novel role for EGFR in the development of CH-induced PH.
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Figure 68: Diagram of Src/EGFR/NOX 2 signaling pathway in VSM of
pulmonary arteries following CH. This pathway is elicited by increases in
intraluminal pressure, membrane depolarization, and ETR stimulation.
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APPENDIX A- Abbreviations and Acronyms

a disintegrin and a metalloproteinase = ADAM
acetylcholine = ACh
caveolin-1 = cav-1
chronic hypoxia = CH
chronic obstructive pulmonary diseases = COPD
diacylglycerol = DAG
dihydroethidium = DHE
endoplasmic reticulum = ER
endothelial nitric oxide synthase = eNOS
endothelin-1 = ET-1
endothelin receptors = ETR
epidermal growth factor = EGF
epidermal growth factor receptor = EGFR
G-protein-coupled receptor = GPCR
hypoxia inducible factor = HIF
hypoxic pulmonary vasoconstriction = HPV
hydrogen peroxide = H2O2
inhibitor = INH
inner diameter = ID
inositol trisphosphate = IP3
left ventricle = LV
matrix metalloproteinase = MMP
155

myosin light chain = MLC
myosin light chain kinase = MLCK
myosin light chain phosphatase = MLCP
NADPH oxidase = NOX
nitric oxide = NO
peroxynitrite = ONOOphosphatidylinositol 4,5-bisphosphate = PIP2
phospholipase C = PLC
physiological saline solution = PSS
polyethylene glycol = PEG
prostaglandin F2α = PGF2α
pulmonary artery smooth muscle cell = PASMC
pulmonary hypertension = PH
reactive oxygen species = ROS
receptor-operated Ca2+ entry = ROCE
right ventricle = RV
right ventricular systolic pressure = RVSP
Rho kinase = ROK
sarcoplasmic reticulum = SR
sarcoplasmic endoplasmic reticulum Ca2+ ATPase = SERCA
septum = S
serotonin = 5-HT
Src homology domain = SH
store-operated Ca2+ entry = SOCE
superoxide anion = O2156

superoxide dismutase = SOD
tissue inhibitor of metalloproteinase = TIMP
transient receptor potential canonical = TRPC
vascular smooth muscle = VSM
voltage gated Ca2+ channels = VGCC
xanthine oxidase = XO
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APPENDIX B- Supplemental Data

Supplemental Figure 1. AP-Cav prevents enhanced vasoconstriction
to KCl following CH. Vasoconstrictor responses to KCl in pressurized,
Ca2+ permeabilized, endothelial disrupted pulmonary arteries from CH and
control rats in the presence of AP-Cav or its scrambled control peptide (50
µM). Values are means ± SE n=5-6/group. *p<0.05 vs. control APScramb. #P< 0.05 CH AP-Scramb.
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Supplemental Figure 2.
Membrane cholesterol prevents EGFdependent vasoconstriction. Vasoconstrictor responses to EGF in
pressurized, Ca2+ permeabilized, endothelial disrupted pulmonary arteries
from CH and control rats in the presence of supplemental cholesterol or
MβCD. Values are means ± SE n=4/group. *p<0.05 vs. vehicle.
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APPENDIX C- Baseline Arterial Diameters
Baseline inner diameters for isolated vessel experiments in arteries stimulated with KCl,
increases in intraluminal pressure (Tone), ET-1, or EGF treated with various inhibitors
(INH) and tone (%) at 300 nM Ca2+ in Ca2+ permeabilized arteries. Values are means 
SE.
Figure/Agonist

Group

Baseline Diameter
(m)

Tone (300
nM Ca2+)

Fig. 12

Control Vehicle

176 ± 19

NA

KCl

CH Vehicle

173 ± 22

NA

Control Apocynin

164 ± 9

NA

CH Apocynin

143 ± 13

NA

Fig. 13A

Control Vehicle

176 ± 9

1.3

KCl

CH Vehicle

151 ± 9

4.0

Control Apocynin

154 ± 7

0.6

CH Apocynin

160 ± 15

4.9

Fig. 13B

Control Vehicle

176 ± 9

1.3

KCl

CH Vehicle

151 ± 9

4.0

Control DPI

160 ± 13

1.6

CH DPI

135 ± 7

4.3

Fig. 14

Control scrambled

156 ± 9

0.7

KCl

CH scrambled

172 ± 16

3.0

Control gp91ds-tat

155 ± 7

1.5

CH gp91ds-tat

144 ± 4

4.5

Fig. 18A

Control Vehicle

144 ± 15

1.7

KCl

CH Vehicle

160 ± 5

5.1

Control SOD

151 ± 22

-0.4

CH SOD

128 ± 21

3.3

160

Figure/Agonist

Group

Baseline Diameter

Fig. 18B

Control Vehicle

144 ± 15

1.7

KCl

CH Vehicle

160 ± 5

5.1

Control Catalase

167 ± 9

1.4

CH Catalase

176 ± 8

7.9

Fig. 19

Control Vehicle

169 ± 24

1.9

KCl

CH Vehicle

154 ± 11

4.0

Control NSC 23766

153 ± 20

2.4

CH NSC 23766

182 ± 11

5.0

Fig. 23

Control Vehicle

136 ± 9

NA

Tone

CH Vehicle

124 ± 5

NA

Control Apocynin

138 ± 10

NA

CH Apocynin

146 ± 13

NA

Fig. 24

Control scrambled

152 ± 17

NA

Tone

CH scrambled

139 ± 9

NA

Control gp91ds-tat

149 ± 8

NA

CH gp91ds-tat

156 ± 14

NA

Fig. 25

Control Vehicle

159 ± 10

NA

Tone

CH Vehicle

143 ± 10

NA

Control NSC 23766

135 ± 10

NA

CH NSC 23766

151 ± 10

NA

161

Tone (300
nM Ca2+)

Figure/Agonist

Group

Baseline Diameter

Tone (300 nM
Ca2+)

Fig. 26A

Control Vehicle

150 ± 14

NA

Tone

CH Vehicle

165 ± 11

NA

Control SOD

125 ± 8

NA

CH SOD

138 ± 24

NA

Fig. 26B

Control Vehicle

150 ± 14

NA

Tone

CH Vehicle

165 ± 11

NA

Control Catalase

149 ± 4

NA

CH Catalase

156 ± 14

NA

Fig. 28

Control scrambled

188 ± 13

-0.3

ET-1

CH scrambled

167 ± 13

5.0

Control gp91ds-tat

138 ± 10

1.4

CH gp91ds-tat

159 ± 11

4.9

Fig. 29

Control Vehicle

155 ± 10

1.1

ET-1

CH Vehicle

164 ± 10

3.8

Control NSC 23766

173 ± 13

2.4

CH NSC 23766

145 ± 16

3.5

Fig. 31

Control Vehicle

169 ± 24

1.9

KCl

CH Vehicle

154 ± 11

4.0

Control AG1478

162 ± 16

1.3

CH AG1478

162 ± 11

5.7

162

Figure/Agonist

Group

Baseline Diameter

Tone (300 nM
Ca2+)

Fig. 36A

Control Vehicle

180 ± 10

2.2

KCl

CH Vehicle

177 ± 6

4.9

Control SU6656

164 ± 12

2.0

CH SU6656

165 ± 15

3.7

Fig. 36B

Control Vehicle

180 ± 10

2.2

KCl

CH Vehicle

177 ± 6

4.9

Control PP2

157 ± 11

2.0

CH PP2

155 ± 13

3.6

Fig. 37A

Control Vehicle

163 ± 10

NA

Tone

CH Vehicle

152 ± 10

NA

Control AG1478

174 ± 19

NA

CH AG1478

150 ± 16

NA

Fig. 37B

Control Vehicle

163 ± 10

NA

Tone

CH Vehicle

152 ± 10

NA

Control Gefitinib

166 ± 17

NA

CH Gefitinib

145 ± 21

NA

Fig. 38

Control Vehicle

159 ± 13

NA

Tone

CH Vehicle

143 ± 9

NA

Control SU6656

131 ± 4

NA

CH SU6656

153 ± 10

NA

163

Figure/Agonist

Group

Baseline Diameter

Tone (300 nM
Ca2+)

Fig. 39

Control Vehicle

142 ± 16

2.8

ET-1

CH Vehicle

161 ± 16

6.2

Control AG1478

152 ± 11

2.4

CH AG1478

159 ± 15

3.5

Fig. 40

Control Vehicle

142 ± 16

2.8

ET-1

CH Vehicle

161 ± 16

6.2

Control SU6656

152 ± 21

2.5

CH SU6656

159 ± 15

4.2

Fig. 44

Control Vehicle

173 ± 15

NA

EGF

CH Vehicle

172 ± 12

NA

Fig. 45A

Control Vehicle

173 ± 15

NA

EGF

CH Vehicle

172 ± 12

NA

Control HA-1077

138 ± 9

NA

CH HA-1077

154 ± 16

NA

Fig. 45B

Control Vehicle

143 ± 15

NA

EGF

CH Vehicle

146 ± 13

NA

Control gp91ds-tat

143 ± 21

NA

CH gp91ds-tat

162 ± 16

NA
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Figure/Agonist

Group

Baseline Diameter

Tone (300
nM Ca2+)

Fig. 46A

Control Vehicle

152 ± 10

NA

EGF

CH Vehicle

157 ± 19

NA

Control AG1478

153 ± 17

NA

CH AG1478

147 ± 16

NA

Fig. 46B

Control Vehicle

136 ± 14

NA

EGF

CH Vehicle

173 ± 5

NA

Control SU6656

148 ± 17

NA

CH SU6656

145 ± 10

NA

Fig. 47

Control Vehicle

144 ± 10

2.9

ET-1

CH Vehicle

180 ± 8

5.4

Control GM6001

161 ± 12

2.1

CH GM6001

174 ± 12

6.0

Fig. 48

Control Vehicle

155 ± 17

0.6

ET-1

CH Vehicle

158 ± 11

5.0

Control MMP2 INH3

167 ± 16

0.5

CH MMP2 INH3

160 ± 12

4.2

Fig. 50

Control Vehicle

155 ± 17

0.7

ET-1

CH Vehicle

158 ± 11

5.0

Control MMP9 INH2

161 ± 14

1.2

CH MMP9 INH2

176 ± 5

4.4
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Figure/Agonist

Group

Baseline Diameter

Tone (300
nM Ca2+)

Fig. 52

Control Vehicle

156 ± 6

2.5

ET-1

CH Vehicle

165 ± 14

3.4

Control TAPI

160 ± 16

1.5

CH TAPI

150 ± 21

4.3

Fig. 54

Control Vehicle

133 ± 13

2.5

KCl

CH Vehicle

185 ± 12

4.2

Control BQ

169 ± 7

1.6

CH BQ

163 ± 10

4.8

Fig. 55

CH Vehicle

139 ± 8

NA

Tone

CH BQ

148 ± 19

NA

Fig. 62

Control Vehicle

136 ± 10

NA

Tone

CH Vehicle

124 ± 5

NA

Control Valinomycin

152 ± 19

NA

CH Valinomycin

153 ± 7

NA

Fig. 65

Control Vehicle

145 ± 14

NA

Tone

CH Vehicle

148 ± 7

NA

Control Pinacidil

161 ± 19

NA

CH Pinacidil

161 ± 12

NA

Fig. 67

Control Vehicle

160 ± 9

0.1

ET-1

CH Vehicle

174 ± 17

1.6

Control Valinomycin

174 ± 6

1.2

CH Valinomycin

168 ± 11

7.0
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